- transforming growth factor beta-1
- transforming growth factor-beta-activated kinase 1 (tak1)
- beta platelet-derived growth factor receptor
- beta-type platelet-derived growth factor receptor
- platelet-derived growth factor receptor alpha /beta
- platelet-derived growth factor receptor beta (pdgfrb)
- insulin-like growth factor 1 receptor beta chain
- pdgfr-beta/platelet-derived growth factor receptor alpha
- epidermal growth factor receptor
- fibroblast growth factor receptor
- growth factor-like peptide
- hepatocyte growth factor receptor
- keratinocyte growth factor receptor
- pro-epidermal growth factor
- epidermal growth factor receptor (egfr)
- epidermal growth factor receptor [g719s]
- epidermal growth factor receptor [s768i]
- epidermal growth factor receptor(l858r)
- epidermal/hepatocyte growth factor receptor
- fibroblast growth factor receptor 1
- fibroblast growth factor receptor 2
- fibroblast growth factor receptor 3
- hepatocyte growth factor receptor (hgfr)
- hepatocyte growth factor receptor (met)
- hepatocyte growth factor receptor [d1228h]
- hepatocyte growth factor receptor [d1228n]
- hepatocyte growth factor receptor [l1195v]
- hepatocyte growth factor receptor [y1230c]
- nt-3 growth factor receptor
- slow nerve growth factor receptor
- vascular endothelial growth factor receptor
- epidermal growth factor receptor (egfr)(del19)
- epidermal growth factor receptor (egfr)(l861q)
- epidermal growth factor receptor (egfr)(t790m)
- epidermal growth factor receptor (t790m/l858r)
- epidermal growth factor receptor [1-973]
- epidermal growth factor receptor [645-1186]
- epidermal growth factor receptor [695-1022]
- epidermal growth factor receptor [l858r,c797s]
- epidermal growth factor receptor(l858r, t790m)
- epidermal growth factor receptor/interleukin-3
- fibroblast growth factor 1 (fgf-1)
- fibroblast growth factor receptor 2 (fgfr2)
- fibroblast growth factor receptor 3 (fgfr3)
- fibroblast growth factor receptor 4 (fgfr4)
- growth factor receptor-bound protein 2
- hepatocyte growth factor receptor (met)(del14)
- hepatocyte growth factor receptor (met)(f1200i)
- hepatocyte growth factor receptor (met)(y1230h)
- hepatocyte growth factor receptor (met)(y1230s)
- hepatocyte growth factor receptor [1038-1346]
- hepatocyte growth factor receptor [960-1390]
- platelet-derived endothelial cell growth factor
- platelet-derived growth factor a chain
- platelet-derived growth factor receptor (d842v)
- platelet-derived growth factor receptor alpha
- vascular endothelial growth factor receptor 2
- alpha-type platelet-derived growth factor receptor
- basic fibroblast growth factor receptor 1 (fgfr1)
- epidermal growth factor receptor (egfr)(del19/c797s)
- epidermal growth factor receptor (egfr)(del19/t790m)
- epidermal growth factor receptor (egfr)(t790m/l858r)
- epidermal growth factor receptor [1-745,751-967]
- epidermal growth factor receptor [1-751,75360-1210]
- epidermal growth factor receptor [1-999,l858r]
- epidermal growth factor receptor [671-1210,l858r]
- epidermal growth factor receptor [696-1022,l858r]
- epidermal growth factor receptor [696-1022,t790m]
- epidermal growth factor receptor [696-1210,t790m]
- epidermal growth factor receptor [l858r,t790m,c797s]
- fibroblast growth factor receptor 1 (fgfr-1)
- fibroblast growth factor receptor 2 [400-821]
- fibroblast growth factor receptor 2 [406-821]
- fibroblast growth factor receptor 3 (fgfr-3)
- fibroblast growth factor receptor 3 (fgfr3)(v555m)
- fibroblast growth factor receptor 4 [388-802]
- hepatocyte growth factor-like protein alpha chain
- high affinity nerve growth factor receptor [g667c]
- mast/stem cell growth factor receptor kit
- mast/stem cell growth factor receptor precursor
- platelet-derived growth factor receptor alpha (pdgfr +-)
- platelet-derived growth factor receptor alpha (pdgfra)
- vascular endothelial cell growth factor 165 receptor
- vascular endothelial growth factor receptor 1/2
- vascular endothelial growth factor receptor 2 (vegfr2)
- vascular endothelial growth factor receptor kinase 2
- phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform/platelet-derived growth factor receptor beta [525-1106]
- phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/platelet-derived growth factor receptor beta [525-1106]
- beta-factor xiia part 2
- epidermal growth factor receptor [1-745,751-1210,c797s]
- epidermal growth factor receptor [1-745,751-1210,t790m]
- epidermal growth factor receptor [1-746,750-1210,a750p]
- epidermal growth factor receptor [668-1210,t790m,l858r]
- epidermal growth factor receptor [696-1022,t790m,l858r]
- fibroblast growth factor receptor 1/2/3/4
- fibroblast growth factor receptor 2 (fgfr2)(403-822)
- gst-fibroblast growth factor receptor 1 (fgfr-1)
- gst-fibroblast growth factor receptor 3 (fgfr-3)
- hepatocyte growth factor receptor (r974-s1390) (a1209g) (v1290l)
- hepatocyte growth factor receptor [1078-1345,h1094r,l1272v]
- hepatocyte growth factor receptor [1078-1345,m1250t,l1272v]
- hepatocyte growth factor receptor [1078-1345,v1092i,l1272v]
- hepatocyte growth factor receptor [1078-1345,y1230h,l1272v]
- high affinity nerve growth factor receptor (trka)(g595r)
- high affinity nerve growth factor receptor [440-796]
- high affinity nerve growth factor receptor [441-796]
- mast/stem cell growth factor receptor kit [n822k]
- mast/stem cell growth factor receptor kit [v559d]
- mast/stem cell growth factor receptor kit [v560g]
- opioid growth factor receptor-like protein 1 (orl1)
- vascular endothelial cell growth factor 165 receptor 2
- vascular endothelial growth factor receptor 2 [790-1356]
- delta and notch-like epidermal growth factor-related receptor
- epidermal growth factor receptor (egfr)(del 747-752)(p753s)
- epidermal growth factor receptor [1-18,20-1210,t790m,c797s]
- epidermal growth factor receptor [1-18,20-745,747-749,751-1210]
- epidermal growth factor receptor [1-249,301-1210,t790m,l858r]
- epidermal growth factor receptor [1-745,751-1210,t790m,c797s]
- epidermal growth factor receptor [1-746,748-748,750-1210,a750p]
- epidermal growth factor receptor [1-763,'fhea',764-1210]
- epidermal growth factor receptor [1-769,'asv',770-1210]
- epidermal growth factor receptor [1-769,'svd',770-1210]
- epidermal growth factor receptor [1-770,'npg',771-1210]
- epidermal growth factor receptor [1-770,'svd',771-1210]
- epidermal growth factor receptor [1-773,'nph',774-1210]
- epidermal growth factor receptor [669-769,'asv',770-1210]
- epidermal growth factor receptor [695-745,751-1022,t790m,c797s]
- fibroblast growth factor receptor 1 (fgfr1)(aa 308-731)
- fibroblast growth factor receptor 3 (fgfr3)(aa 399-806)
- fibroblast growth factor receptor 4 (fgfr4)(aa 460-802)
- insulin-like growth factor 2 mrna-binding protein 1
- mast/stem cell growth factor receptor kit (v559d/v654a)
- mast/stem cell growth factor receptor kit 1 (d816v)
- mast/stem cell growth factor receptor kit [1-973]
- mast/stem cell growth factor receptor kit [544-976]
- mast/stem cell growth factor receptor kit [v560g,d816v]
- platelet-derived growth factor receptor alpha [551-1089,v561d]
- vascular endothelial growth factor receptor 3 (short) [798-1298]
- vascular endothelial growth factor receptor 3 [818-948,1003-1077]
- catenin beta-1/transcription factor 4
- core-binding factor subunit beta (cbfb)
- transforming protein n-ras
- epidermal growth factor receptor/receptor tyrosine-protein kinase erbb-2
- focal adhesion kinase 1/vascular endothelial growth factor receptor 3
- hepatocyte growth factor receptor met isoform 2 [974-1390,a1209g,v1290l]
- hepatocyte growth factor receptor/proto-oncogene tyrosine-protein kinase receptor ret
- isoform trka-i of high affinity nerve growth factor receptor (trkai)
- trk1-transforming tyrosine kinase protein
- catenin beta-1/transcription factor 7-like 2
- vascular endothelial growth factor receptor 1 and 2 (flt-1 and kdr)
- inhibitor of nuclear factor kappa-b kinase subunit beta
- tyrosine-protein kinase transforming protein src ITC
- phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/vascular endothelial growth factor receptor 2
- rho-associated protein kinase 2/transforming protein rhoa
- transforming protein rhoa/rho-related gtp-binding protein rhoc
- cobra venom factor/complement factor b/complement factor d
- coagulation factor vii/tissue factor
- coagulation factor iii/factor viia (fviia)
- complement factor b and cobra venom factor
- epidermal growth factor receptor/receptor tyrosine-protein kinase erbb-2/receptor tyrosine-protein kinase erbb-3/receptor tyrosine-protein kinase erbb-4
- factor ix
- negative factor
- stuart factor
- growth hormone-releasing peptide
- arf exchange factor
- b1-binding factor
- coagulation factor ii
- coagulation factor ix
- coagulation factor viii
- coagulation factor x
- coagulation factor xa
- coagulation factor xi
- coagulation factor xiia
- coagulation factor xiii
- coagulation factor xiiia
- complement factor b
- corticotropin-releasing factor
- factor xa (fxa)
- scatter factor receptor
- stuart-prower factor
- transcription factor ap1
- transcription factor jun
- transcription factor p65
- transcription factor stat3
- corticotropin-releasing factor receptor 2/corticotropin-releasing factor-binding protein
- growth arrest-specific protein 6
- beta-hexosaminidase subunit beta
- beta-1/beta-2/beta-3 adrenergic receptor
- beta-hexosaminidase subunit alpha/beta
- 45 kda-splicing factor
- ccg1-interacting factor a
- ccr4-associated factor 1
- cftr inhibitory factor, cif
- coagulation factor ix/viii
- coagulation factor x precursor
- complement decay-accelerating factor
- corticotropin releasing factor receptor
- elongation factor 4 homolog
- eukaryotic translation initation factor
- factor vii light chain
- homeodomain transcription factor pdf2
- interferon gamma-inducing factor
- lethal factor/protective antigen
- neutrophil cytosol factor 1
- neutrophil cytosolic factor 1
- paf platelet activating factor
- pigment epithelium-derived factor
- platelet-activating factor acetylhydrolase
- transcription factor dp-2
- transcription factor sox-18
- bdnf/nt-3 growth factors receptor
- growth hormone secretagogue receptor type 1
- growth hormone secretagogue receptor type 1/isoform 1b of growth hormone secretagogue receptor type 1 (1b)
- kelch-like ech-associated protein 1/nuclear factor erythroid 2-related factor 2
- actin nucleation-promoting factor wasl
- activated factor xa heavy chain
- coagulation factor v heavy chain
- coagulation factor x/antithrombin iii
- coagulation factor xiii a (fxiiia)
- coagulation factor xiii a chain
- coagulation factor xiii b chain
- colony stimulating factor 1 receptor
- complement factor d [24-253]
- corticotropin releasing factor receptor 1
- corticotropin releasing factor receptor 2
- corticotropin releasing factor-binding protein
- corticotropin-releasing factor receptor 1
- corticotropin-releasing factor receptor 2
- eukaryotic initiation factor 4a-ii
- granulocyte colony-stimulating factor receptor
- granulocyte-macrophage colony-stimulating factor
- hypoxia-inducible factor (hif-ph2)
- hypoxia-inducible factor 1-alpha
- hypoxia-inducible factor prolyl hydroxylase
- macrophage migration inhibitory factor (mif)
- nuclear factor nf-kappa-b
- platelet factor 4, short form
- protein fosb/transcription factor jund
- rna polymerase sigma factor sigb
- tbp-associated factor 210 kda
- transcription factor 7-like 2
- transcription factor stat1:stat3 dimer
- tumor necrosis factor alpha (tnf)
- tumor-derived hypophosphatemia-inducing factor
Beta-Sitosterone Beta-Sitostenone BDBM50488934
CHEMBL206472 BDBM50188423 beta,beta-dimethylmelatonin
US8697715, Beta US9259470, Beta BDBM120127
BDBM50221818 1-alpha-acetoxy-6-beta,9-beta-difuroyl-beta-agarofuranoxy-4-beta-hydroxy-2-alpha-nicotinoyloxydihydro-beta-agarofuran CHEMBL232905
BDBM82409 Beta MSH beta MSH, human
- Harikrishnan, LS; Warrier, J; Tebben, AJ; Tonukunuru, G; Madduri, SR; Baligar, V; Mannoori, R; Seshadri, B; Rahaman, H; Arunachalam, PN; Dikundwar, AG; Fink, BE; Fargnoli, J; Fereshteh, M; Fan, Y; Lippy, J; Ho, CP; Wautlet, B; Sheriff, S; Ruzanov, M; Borzilleri, RM Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI). Bioorg Med Chem 26: 1026-1034 (2018)
- Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
- Li, HY; Wang, Y; Heap, CR; King, CH; Mundla, SR; Voss, M; Clawson, DK; Yan, L; Campbell, RM; Anderson, BD; Wagner, JR; Britt, K; Lu, KX; McMillen, WT; Yingling, JM Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J Med Chem 49: 2138-42 (2006)
- Geldenhuys, WJ; Nakamura, H 3D-QSAR and docking studies on transforming growth factor (TGF)-beta receptor 1 antagonists. Bioorg Med Chem Lett 20: 1918-23 (2010)
- Li, HY; McMillen, WT; Heap, CR; McCann, DJ; Yan, L; Campbell, RM; Mundla, SR; King, CH; Dierks, EA; Anderson, BD; Britt, KS; Huss, KL; Voss, MD; Wang, Y; Clawson, DK; Yingling, JM; Sawyer, JS Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-beta Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-beta Receptor Type I Inhibitor as Antitumor Agent. J Med Chem 51: 2302-2306 (2008)
- Goldberg, FW; Ward, RA; Powell, SJ; Debreczeni, JE; Norman, RA; Roberts, NJ; Dishington, AP; Gingell, HJ; Wickson, KF; Roberts, AL Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5). J Med Chem 52: 7901-5 (2009)
- Ren, JX; Li, LL; Zou, J; Yang, L; Yang, JL; Yang, SY Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. Eur J Med Chem 44: 4259-65 (2009)
- Shimizu, T; Kimura, K; Sakai, T; Kawakami, K; Miyazaki, T; Nakouji, M; Ogawa, A; Ohuchi, H; Shimizu, K Synthesis and evaluation of [2-(4-quinolyloxy)phenyl]methanone derivatives: novel selective inhibitors of transforming growth factor-beta kinase. J Med Chem 51: 3326-9 (2008)
- Fakhouri, L; El-Elimat, T; Hurst, DP; Reggio, PH; Pearce, CJ; Oberlies, NH; Croatt, MP Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analogues. Bioorg Med Chem 23: 6993-9 (2015)
- Miwa, S; Yokota, M; Ueyama, Y; Maeda, K; Ogoshi, Y; Seki, N; Ogawa, N; Nishihata, J; Nomura, A; Adachi, T; Kitao, Y; Nozawa, K; Ishikawa, T; Ukaji, Y; Shiozaki, M Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents. ACS Med Chem Lett 12: 745-751 (2021)
- Sawyer, JS; Anderson, BD; Beight, DW; Campbell, RM; Jones, ML; Herron, DK; Lampe, JW; McCowan, JR; McMillen, WT; Mort, N; Parsons, S; Smith, EC; Vieth, M; Weir, LC; Yan, L; Zhang, F; Yingling, JM Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46: 3953-6 (2003)
- Kim, DK; Jang, Y; Lee, HS; Park, HJ; Yoo, J Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem 50: 3143-7 (2007)
- Li, X; Wang, L; Long, L; Xiao, J; Hu, Y; Li, S Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5). Bioorg Med Chem Lett 19: 4868-72 (2009)
- Callahan, JF; Burgess, JL; Fornwald, JA; Gaster, LM; Harling, JD; Harrington, FP; Heer, J; Kwon, C; Lehr, R; Mathur, A; Olson, BA; Weinstock, J; Laping, NJ Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45: 999-1001 (2002)
- Kim, DK; Lee, YI; Lee, YW; Dewang, PM; Sheen, YY; Kim, YW; Park, HJ; Yoo, J; Lee, HS; Kim, YK Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. Bioorg Med Chem 18: 4459-67 (2010)
- Lou, LL; Ni, FQ; Chen, L; Shaker, S; Li, W; Wang, R; Tang, GH; Yin, S Germacrane Sesquiterpenoids as a New Type of Anticardiac Fibrosis Agent Targeting Transforming Growth Factor β Type I Receptor. J Med Chem 62: 7961-7975 (2019)
- Powell, J; Mota, F; Steadman, D; Soudy, C; Miyauchi, JT; Crosby, S; Jarvis, A; Reisinger, T; Winfield, N; Evans, G; Finniear, A; Yelland, T; Chou, YT; Chan, AWE; O'Leary, A; Cheng, L; Liu, D; Fotinou, C; Milagre, C; Martin, JF; Jia, H; Frankel, P; Djordjevic, S; Tsirka, SE; Zachary, IC; Selwood, DL Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells. J Med Chem 61: 4135-4154 (2018)
- Roth, GJ; Heckel, A; Brandl, T; Grauert, M; Hoerer, S; Kley, JT; Schnapp, G; Baum, P; Mennerich, D; Schnapp, A; Park, JE Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factorß receptor I (TGFßRI). J Med Chem 53: 7287-95 (2010)
- Amada, H; Sekiguchi, Y; Ono, N; Matsunaga, Y; Koami, T; Asanuma, H; Shiozawa, F; Endo, M; Ikeda, A; Aoki, M; Fujimoto, N; Wada, R; Sato, M Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-ß type I receptor kinase. Bioorg Med Chem Lett 22: 2024-9 (2012)
- Guo, C; Zhang, C; Li, X; Li, W; Xu, Z; Bao, L; Ding, Y; Wang, L; Li, S Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-ß type I receptor (ALK5). Bioorg Med Chem Lett 23: 5850-4 (2013)
- Jin, CH; Krishnaiah, M; Sreenu, D; Rao, KS; Subrahmanyam, VB; Park, CY; Son, JY; Sheen, YY; Kim, DK Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Bioorg Med Chem 19: 2633-40 (2011)
- Li, HY; Wang, Y; Yan, L; Campbell, RM; Anderson, BD; Wagner, JR; Yingling, JM Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. Bioorg Med Chem Lett 14: 3585-8 (2004)
- BLANK, BR; GIBBONS, PA; NDUBAKU, C; ROMERO, FA; CHANG, JH; PHAM, JD; ROBERTS, TC; VEKARIYA, RH; JEANNERET, AD; SILVA, H; DADA, RO; McINTOSH, KC; NEIGER, E; BROWN, W; TAKASAKI, H; CRIFAR, CC; POLAT, DE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR US Patent US20250034159 (2025)
- Xu, G; Zhang, Y; Wang, H; Guo, Z; Wang, X; Li, X; Chang, S; Sun, T; Yu, Z; Xu, T; Zhao, L; Wang, Y; Yu, W Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors. Eur J Med Chem 198: (2020)
- Kaldor, SW; Tyhonas, J; Murphy, EA; Kanouni, T; Arnold, LD; Kania, R; Cox, JM Inhibitors of fibroblast growth factor receptor kinases US Patent US11345681 (2022)
- Miduturu, CV Inhibitors of the fibroblast growth factor receptor US Patent US10196436 (2019)
- Li, F; Park, Y; Hah, JM; Ryu, JS Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-ß type 1 receptor kinase inhibitors. Bioorg Med Chem Lett 23: 1083-6 (2013)
- Amada, H; Sekiguchi, Y; Ono, N; Koami, T; Takayama, T; Yabuuchi, T; Katakai, H; Ikeda, A; Aoki, M; Naruse, T; Wada, R; Nozoe, A; Sato, M 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-ß type I receptor inhibitors. Bioorg Med Chem 20: 7128-38 (2012)
- Gellibert, F; de Gouville, AC; Woolven, J; Mathews, N; Nguyen, VL; Bertho-Ruault, C; Patikis, A; Grygielko, ET; Laping, NJ; Huet, S Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J Med Chem 49: 2210-21 (2006)
- Verner, E; Brameld, KA Quinolone derivatives as fibroblast growth factor receptor inhibitors US Patent US11078199 (2021)
- Jin, CH; Sreenu, D; Krishnaiah, M; Subrahmanyam, VB; Rao, KS; Nagendra Mohan, AV; Park, CY; Son, JY; Son, DH; Park, HJ; Sheen, YY; Kim, DK Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-ß type 1 receptor kinase inhibitors. Eur J Med Chem 46: 3917-25 (2011)
- Kammasud, N; Boonyarat, C; Tsunoda, S; Sakurai, H; Saiki, I; Grierson, DS; Vajragupta, O Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 17: 4812-8 (2007)
- Chen, L; Guan, D; Bai, H; Yan, X; Miao, S; Zhu, S Substituted pyrazoles as inhibitors of fibroblast growth factor receptor US Patent US10214515 (2019)
- Musumeci, F; Radi, M; Brullo, C; Schenone, S Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem 55: 10797-822 (2012)
- Jin, CH; Krishnaiah, M; Sreenu, D; Subrahmanyam, VB; Rao, KS; Mohan, AV; Park, CY; Son, JY; Sheen, YY; Kim, DK Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-ß type 1 receptor kinase inhibitors. Bioorg Med Chem Lett 21: 6049-53 (2011)
- Jin, CH; Krishnaiah, M; Sreenu, D; Subrahmanyam, VB; Park, HJ; Park, SJ; Sheen, YY; Kim, DK 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-ß type I receptor kinase. Bioorg Med Chem 22: 2724-32 (2014)
- Krishnaiah, M; Jin, CH; Sheen, YY; Kim, DK Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-ß type I receptor kinase. Bioorg Med Chem Lett 25: 5228-31 (2015)
- Miura, T; Matsuo, A; Muraoka, T; Ide, M; Morikami, K; Kamikawa, T; Nishihara, M; Kashiwagi, H Identification of a selective inhibitor of transforming growth factorß-activated kinase 1 by biosensor-based screening of focused libraries. Bioorg Med Chem Lett 27: 1031-1036 (2017)
- Eaton, SR; Cody, WL; Doherty, AM; Holland, DR; Panek, RL; Lu, GH; Dahring, TK; Rose, DR Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity. J Med Chem 41: 4329-42 (1998)
- Uings, IJ; Spacey, GD; Bonser, RW Effects of the indolocarbazole 3744W on the tyrosine kinase activity of the cytoplasmic domain of the platelet-derived growth factor beta-receptor. Cell Signal 11: 95-100 (1999)
- Venukadasula, PK; Owusu, BY; Bansal, N; Ross, LJ; Hobrath, JV; Bao, D; Truss, JW; Stackhouse, M; Messick, TE; Klampfer, L; Galemmo, RA Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett 7: 177-81 (2016)
- Wang, Y; Li, L; Fan, J; Dai, Y; Jiang, A; Geng, M; Ai, J; Duan, W Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. J Med Chem 61: 9085-9104 (2018)
- Chan, BK; Hanan, EJ; Bowman, KK; Bryan, MC; Burdick, D; Chan, E; Chen, Y; Clausen, S; Dela Vega, T; Dotson, J; Eigenbrot, C; Elliott, RL; Heald, RA; Jackson, PS; Knight, JD; La, H; Lainchbury, MD; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Seward, EM; Sideris, S; Shao, L; Wang, S; Yeap, SK; Yen, I; Yu, C; Heffron, TP Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem 59: 9080-9093 (2016)
- Carmi, C; Galvani, E; Vacondio, F; Rivara, S; Lodola, A; Russo, S; Aiello, S; Bordi, F; Costantino, G; Cavazzoni, A; Alfieri, RR; Ardizzoni, A; Petronini, PG; Mor, M Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. J Med Chem 55: 2251-64 (2012)
- MAGAVI, SS; PARKS, DJ; TAIT, BD; CHO, J; AGRAWAL, R; SHAW, PR PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF US Patent US20250129067 (2025)
- Ishikawa, T; Seto, M; Banno, H; Kawakita, Y; Oorui, M; Taniguchi, T; Ohta, Y; Tamura, T; Nakayama, A; Miki, H; Kamiguchi, H; Tanaka, T; Habuka, N; Sogabe, S; Yano, J; Aertgeerts, K; Kamiyama, K Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 54: 8030-50 (2011)
- Hubbard, RD; Bamaung, NY; Fidanze, SD; Erickson, SA; Palazzo, F; Wilsbacher, JL; Zhang, Q; Tucker, LA; Hu, X; Kovar, P; Osterling, DJ; Johnson, EF; Bouska, J; Wang, J; Davidsen, SK; Bell, RL; Sheppard, GS Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorg Med Chem Lett 19: 1718-21 (2009)
- Fidanze, SD; Erickson, SA; Wang, GT; Mantei, R; Clark, RF; Sorensen, BK; Bamaung, NY; Kovar, P; Johnson, EF; Swinger, KK; Stewart, KD; Zhang, Q; Tucker, LA; Pappano, WN; Wilsbacher, JL; Wang, J; Sheppard, GS; Bell, RL; Davidsen, SK; Hubbard, RD Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorg Med Chem Lett 20: 2452-5 (2010)
- Krishnaiah, M; Jin, CH; Sreenu, D; Subrahmanyam, VB; Rao, KS; Son, DH; Park, HJ; Kim, SW; Sheen, YY; Kim, DK Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-ß type 1 receptor kinase inhibitors. Eur J Med Chem 57: 74-84 (2012)
- Tomassi, S; Lategahn, J; Engel, J; Keul, M; Tumbrink, HL; Ketzer, J; Mühlenberg, T; Baumann, M; Schultz-Fademrecht, C; Bauer, S; Rauh, D Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. J Med Chem 60: 2361-2372 (2017)
- Li, C; Dai, Y; Kong, X; Wang, B; Peng, X; Wu, H; Shen, Y; Yang, Y; Ji, Y; Wang, D; Li, S; Li, X; Shi, Y; Geng, M; Zheng, M; Ai, J; Liu, H Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors. J Med Chem 66: 3226-3249 (2023)
- Kawakita, Y; Banno, H; Ohashi, T; Tamura, T; Yusa, T; Nakayama, A; Miki, H; Iwata, H; Kamiguchi, H; Tanaka, T; Habuka, N; Sogabe, S; Ohta, Y; Ishikawa, T Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders. J Med Chem 55: 3975-91 (2012)
- Dolle, RE; Dunn, JA; Bobko, M; Singh, B; Kuster, JE; Baizman, E; Harris, AL; Sawutz, DG; Miller, D; Wang, S 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem 37: 2627-9 (1994)
- Polverino, A; Coxon, A; Starnes, C; Diaz, Z; DeMelfi, T; Wang, L; Bready, J; Estrada, J; Cattley, R; Kaufman, S; Chen, D; Gan, Y; Kumar, G; Meyer, J; Neervannan, S; Alva, G; Talvenheimo, J; Montestruque, S; Tasker, A; Patel, V; Radinsky, R; Kendall, R AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66: 8715-21 (2006)
- Mo, C; Zhang, Z; Guise, CP; Li, X; Luo, J; Tu, Z; Xu, Y; Patterson, AV; Smaill, JB; Ren, X; Lu, X; Ding, K 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Med Chem Lett 8: 543-548 (2017)
- BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
- Ambaye, ND; Gunzburg, MJ; Lim, RC; Price, JT; Wilce, MC; Wilce, JA Benzopyrazine derivatives: A novel class of growth factor receptor bound protein 7 antagonists. Bioorg Med Chem 19: 693-701 (2011)
- Wu, L; Zhang, C; He, C; Qian, D; Lu, L; Sun, Y; Xu, M; Zhuo, J; Liu, PCC; Klabe, R; Wynn, R; Covington, M; Gallagher, K; Leffet, L; Bowman, K; Diamond, S; Koblish, H; Zhang, Y; Soloviev, M; Hollis, G; Burn, TC; Scherle, P; Yeleswaram, S; Huber, R; Yao, W Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. J Med Chem 64: 10666-10679 (2021)
- Heald, R; Bowman, KK; Bryan, MC; Burdick, D; Chan, B; Chan, E; Chen, Y; Clausen, S; Dominguez-Fernandez, B; Eigenbrot, C; Elliott, R; Hanan, EJ; Jackson, P; Knight, J; La, H; Lainchbury, M; Malek, S; Mann, S; Merchant, M; Mortara, K; Purkey, H; Schaefer, G; Schmidt, S; Seward, E; Sideris, S; Shao, L; Wang, S; Yeap, K; Yen, I; Yu, C; Heffron, TP Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 58: 8877-95 (2015)
- Hu, M; Ye, W; Li, J; Zhong, G; He, G; Xu, Q; Zhang, Y Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors. Chem Biol Drug Des 85: 280-9 (2015)
- Mahboobi, S; Sellmer, A; Winkler, M; Eichhorn, E; Pongratz, H; Ciossek, T; Baer, T; Maier, T; Beckers, T Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem 53: 8546-55 (2010)
- Muraoka, T; Ide, M; Morikami, K; Irie, M; Nakamura, M; Miura, T; Kamikawa, T; Nishihara, M; Kashiwagi, H Discovery of a potent and highly selective transforming growth factorß receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD). Bioorg Med Chem 24: 4206-4217 (2016)
- Tsou, HR; Mamuya, N; Johnson, BD; Reich, MF; Gruber, BC; Ye, F; Nilakantan, R; Shen, R; Discafani, C; DeBlanc, R; Davis, R; Koehn, FE; Greenberger, LM; Wang, YF; Wissner, A 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 44: 2719-34 (2001)
- VanBrocklin, HF; Lim, JK; Coffing, SL; Hom, DL; Negash, K; Ono, MY; Gilmore, JL; Bryant, I; Riese, DJ Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem 48: 7445-56 (2005)
- Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.
- Cheng, M; Yu, X; Lu, K; Xie, L; Wang, L; Meng, F; Han, X; Chen, X; Liu, J; Xiong, Y; Jin, J Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. J Med Chem 63: 1216-1232 (2020)
- Zhang, W; Zhang, K; Yao, Y; Liu, Y; Ni, Y; Liao, C; Tu, Z; Qiu, Y; Wang, D; Chen, D; Qiang, L; Li, Z; Jiang, S Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. Eur J Med Chem 211: (2021)
- Cui, J; Peng, X; Gao, D; Dai, Y; Ai, J; Li, Y Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors. Bioorg Med Chem Lett 27: 3782-3786 (2017)
- Tan, B; Zhang, X; Quan, X; Zheng, G; Li, X; Zhao, L; Li, W; Li, B Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors. Bioorg Med Chem Lett 30: (2020)
- Borzilleri, RM; Zheng, X; Qian, L; Ellis, C; Cai, ZW; Wautlet, BS; Mortillo, S; Jeyaseelan, R; Kukral, DW; Fura, A; Kamath, A; Vyas, V; Tokarski, JS; Barrish, JC; Hunt, JT; Lombardo, LJ; Fargnoli, J; Bhide, RS Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem 48: 3991-4008 (2005)
- Knoepfel, T; Furet, P; Mah, R; Buschmann, N; Leblanc, C; Ripoche, S; Graus-Porta, D; Wartmann, M; Galuba, I; Fairhurst, RA 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4. ACS Med Chem Lett 9: 215-220 (2018)
- Li, SN; Xu, YY; Gao, JY; Yin, HR; Zhang, SL; Li, HQ Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors. Bioorg Med Chem 23: 3221-7 (2015)
- Liu, G; Campbell, BT; Holladay, MW; Ford Pulido, JM; Hua, H; Gitnick, D; Gardner, MF; James, J; Breider, MA; Brigham, D; Belli, B; Armstrong, RC; Treiber, DK Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. ACS Med Chem Lett 3: 997-1002 (2012)
- Ravindranathan, KP; Mandiyan, V; Ekkati, AR; Bae, JH; Schlessinger, J; Jorgensen, WL Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J Med Chem 53: 1662-72 (2010)
- Gibson, KH; Grundy, W; Godfrey, AA; Woodburn, JR; Ashton, SE; Curry, BJ; Scarlett, L; Barker, AJ; Brown, DS Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines Bioorg Med Chem Lett 7: 2723-2728 (1997)
- Coumar, MS; Chu, CY; Lin, CW; Shiao, HY; Ho, YL; Reddy, R; Lin, WH; Chen, CH; Peng, YH; Leou, JS; Lien, TW; Huang, CT; Fang, MY; Wu, SH; Wu, JS; Chittimalla, SK; Song, JS; Hsu, JT; Wu, SY; Liao, CC; Chao, YS; Hsieh, HP Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 53: 4980-8 (2010)
- Lu, X; Chen, H; Patterson, AV; Smaill, JB; Ding, K Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. J Med Chem 62: 2905-2915 (2019)
- Kim, SH; Tokarski, JS; Leavitt, KJ; Fink, BE; Salvati, ME; Moquin, R; Obermeier, MT; Trainor, GL; Vite, GG; Stadnick, LK; Lippy, JS; You, D; Lorenzi, MV; Chen, P Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA. Bioorg Med Chem Lett 18: 634-9 (2008)
- Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kettle, JG; Kendrew, J; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bioorg Med Chem Lett 16: 4908-12 (2006)
- Abdel-Magid, AF Inhibitors of the Epidermal Growth Factor Receptor (EGFR) May Provide Effective Treatment for Lung Adenocarcinoma. ACS Med Chem Lett 6: 732-3 (2015)
- Qin, M; Wang, T; Xu, B; Ma, Z; Jiang, N; Xie, H; Gong, P; Zhao, Y Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. Eur J Med Chem 104: 115-26 (2015)
- Carmi, C; Cavazzoni, A; Vezzosi, S; Bordi, F; Vacondio, F; Silva, C; Rivara, S; Lodola, A; Alfieri, RR; La Monica, S; Galetti, M; Ardizzoni, A; Petronini, PG; Mor, M Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem 53: 2038-50 (2010)
- Finlay, MRV; Barton, P; Bickerton, S; Bista, M; Colclough, N; Cross, DAE; Evans, L; Floc'h, N; Gregson, C; Guérot, CM; Hargreaves, D; Kang, X; Lenz, EM; Li, X; Liu, Y; Lorthioir, O; Martin, MJ; McKerrecher, D; McWhirter, C; O'Neill, D; Orme, JP; Mosallanejad, A; Rahi, A; Smith, PD; Talbot, V; Ward, RA; Wrigley, G; Wylot, M; Xue, L; Yao, T; Ye, Y; Zhao, X Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. J Med Chem 64: 13704-13718 (2021)
- Goncalves, V; Gautier, B; Coric, P; Bouaziz, S; Lenoir, C; Garbay, C; Vidal, M; Inguimbert, N Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. J Med Chem 50: 5135-46 (2007)
- Jarvis, A; Allerston, CK; Jia, H; Herzog, B; Garza-Garcia, A; Winfield, N; Ellard, K; Aqil, R; Lynch, R; Chapman, C; Hartzoulakis, B; Nally, J; Stewart, M; Cheng, L; Menon, M; Tickner, M; Djordjevic, S; Driscoll, PC; Zachary, I; Selwood, DL Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem 53: 2215-26 (2010)
- Mohammadi, M; McMahon, G; Sun, L; Tang, C; Hirth, P; Yeh, BK; Hubbard, SR; Schlessinger, J Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-60 (1997)
- Pawar, VG; Sos, ML; Rode, HB; Rabiller, M; Heynck, S; van Otterlo, WA; Thomas, RK; Rauh, D Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J Med Chem 53: 2892-901 (2010)
- Targeting insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) for the treatment of cancer.
- Mulvihill, MJ; Ji, QS; Werner, D; Beck, P; Cesario, C; Cooke, A; Cox, M; Crew, A; Dong, H; Feng, L; Foreman, KW; Mak, G; Nigro, A; O'Connor, M; Saroglou, L; Stolz, KM; Sujka, I; Volk, B; Weng, Q; Wilkes, R 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem Lett 17: 1091-7 (2007)
- Jin, M; Petronella, BA; Cooke, A; Kadalbajoo, M; Siu, KW; Kleinberg, A; May, EW; Gokhale, PC; Schulz, R; Kahler, J; Bittner, MA; Foreman, K; Pachter, JA; Wild, R; Epstein, D; Mulvihill, MJ Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics. ACS Med Chem Lett 4: 627-31 (2013)
- Yu, X; Cheng, M; Lu, K; Shen, Y; Zhong, Y; Liu, J; Xiong, Y; Jin, J Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. J Med Chem 65: 8416-8443 (2022)
- Zhao, F; Lin, Z; Wang, F; Zhao, W; Dong, X Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. Bioorg Med Chem Lett 23: 5385-8 (2013)
- Milik, SN; Lasheen, DS; Serya, RAT; Abouzid, KAM How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem 142: 131-151 (2017)
- Du, J; Lei, B; Qin, J; Liu, H; Yao, X Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J Mol Graph Model 27: 642-54 (2008)
- Wurz, RP; Pettus, LH; Ashton, K; Brown, J; Chen, JJ; Herberich, B; Hong, FT; Hu-Harrington, E; Nguyen, T; St Jean, DJ; Tadesse, S; Bauer, D; Kubryk, M; Zhan, J; Cooke, K; Mitchell, P; Andrews, KL; Hsieh, F; Hickman, D; Kalyanaraman, N; Wu, T; Reid, DL; Lobenhofer, EK; Andrews, DA; Everds, N; Guzman, R; Parsons, AT; Hedley, SJ; Tedrow, J; Thiel, OR; Potter, M; Radinsky, R; Beltran, PJ; Tasker, AS Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett 6: 987-92 (2015)
- Wurster, JA; Malone, TC; Hull, III, CE; Rao, S; Yang, R; Yee, R Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 US Patent US9296747 (2016)
- Hubbard, RD; Bamaung, NY; Palazzo, F; Zhang, Q; Kovar, P; Osterling, DJ; Hu, X; Wilsbacher, JL; Johnson, EF; Bouska, J; Wang, J; Bell, RL; Davidsen, SK; Sheppard, GS Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR). Bioorg Med Chem Lett 17: 5406-9 (2007)
- Novoa, A; Pellegrini-Moïse, N; Bechet, D; Barberi-Heyob, M; Chapleur, Y Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1. Bioorg Med Chem 18: 3285-98 (2010)
- Han, C; Wan, L; Ji, H; Ding, K; Huang, Z; Lai, Y; Peng, S; Zhang, Y Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. Eur J Med Chem 77: 75-83 (2014)
- Maity, P; Chatterjee, J; Patil, KT; Arora, S; Katiyar, MK; Kumar, M; Samarbakhsh, A; Joshi, G; Bhutani, P; Chugh, M; Gavande, NS; Kumar, R Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. J Med Chem 66: 3135-3172 (2023)
- ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
- Traxler, P; Trinks, U; Buchdunger, E; Mett, H; Meyer, T; Müller, M; Regenass, U; Rösel, J; Lydon, N [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J Med Chem 38: 2441-8 (1995)
- Glenn, MP; Kahnberg, P; Boyle, GM; Hansford, KA; Hans, D; Martyn, AC; Parsons, PG; Fairlie, DP Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J Med Chem 47: 2984-94 (2004)
- Gautier, B; Goncalves, V; Diana, D; Di Stasi, R; Teillet, F; Lenoir, C; Huguenot, F; Garbay, C; Fattorusso, R; D'Andrea, LD; Vidal, M; Inguimbert, N Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem 53: 4428-40 (2010)
- Song, J; Jang, S; Lee, JW; Jung, D; Lee, S; Min, KH Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors. Bioorg Med Chem Lett 29: 477-480 (2019)
- Fan, J; Dai, Y; Shao, J; Peng, X; Wang, C; Cao, S; Zhao, B; Ai, J; Geng, M; Duan, W Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorg Med Chem Lett 26: 2594-9 (2016)
- Ye, X; Gaucher, JF; Hu, H; Wang, L; Broussy, S Dimer Peptide Ligands of Vascular Endothelial Growth Factor: Optimizing Linker Length for High Affinity and Antiangiogenic Activity. J Med Chem 66: 9753-9765 (2023)
- Buchanan, JL; Newcomb, JR; Carney, DP; Chaffee, SC; Chai, L; Cupples, R; Epstein, LF; Gallant, P; Gu, Y; Harmange, JC; Hodge, K; Houk, BE; Huang, X; Jona, J; Joseph, S; Jun, HT; Kumar, R; Li, C; Lu, J; Menges, T; Morrison, MJ; Novak, PM; van der Plas, S; Radinsky, R; Rose, PE; Sawant, S; Sun, JR; Surapaneni, S; Turci, SM; Xu, K; Yanez, E; Zhao, H; Zhu, X Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Bioorg Med Chem Lett 21: 2394-9 (2011)
- Xiao, Q; Qu, R; Gao, D; Yan, Q; Tong, L; Zhang, W; Ding, J; Xie, H; Li, Y Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. Bioorg Med Chem 24: 2673-80 (2016)
- Xu, YY; Li, SN; Yu, GJ; Hu, QH; Li, HQ Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity. Bioorg Med Chem 21: 6084-91 (2013)
- Bower, KE; Lam, SN; Oates, BD; Del Rosario, JR; Corner, E; Osothprarop, TF; Kinhikar, AG; Hoye, JA; Preston, RR; Murphy, RE; Campbell, LA; Huang, H; Jimenez, J; Cao, X; Chen, G; Ainekulu, ZW; Datt, AB; Levin, NJ; Doppalapudi, VR; Pirie-Shepherd, SR; Bradshaw, C; Woodnutt, G; Lappe, RW Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery. J Med Chem 54: 1256-65 (2011)
- Harmange, JC; Weiss, MM; Germain, J; Polverino, AJ; Borg, G; Bready, J; Chen, D; Choquette, D; Coxon, A; DeMelfi, T; DiPietro, L; Doerr, N; Estrada, J; Flynn, J; Graceffa, RF; Harriman, SP; Kaufman, S; La, DS; Long, A; Martin, MW; Neervannan, S; Patel, VF; Potashman, M; Regal, K; Roveto, PM; Schrag, ML; Starnes, C; Tasker, A; Teffera, Y; Wang, L; White, RD; Whittington, DA; Zanon, R Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem 51: 1649-67 (2008)
- Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.
- Jin, M; Kleinberg, A; Cooke, A; Gokhale, PC; Foreman, K; Dong, H; Siu, KW; Bittner, MA; Mulvihill, KM; Yao, Y; Landfair, D; O'Connor, M; Mak, G; Pachter, JA; Wild, R; Rosenfeld-Franklin, M; Ji, Q; Mulvihill, MJ Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg Med Chem Lett 21: 1176-80 (2011)
- Domarkas, J; Dudouit, F; Williams, C; Qiyu, Q; Banerjee, R; Brahimi, F; Jean-Claude, BJ The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 49: 3544-52 (2006)
- Thompson, AM; Delaney, AM; Hamby, JM; Schroeder, MC; Spoon, TA; Crean, SM; Showalter, HD; Denny, WA Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J Med Chem 48: 4628-53 (2005)
- Kiselyov, AS; Piatnitski, E; Milligan, D; Ouyang, X 1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. Chem Biol Drug Des 69: 331-7 (2007)
- Hanan, EJ; Baumgardner, M; Bryan, MC; Chen, Y; Eigenbrot, C; Fan, P; Gu, XH; La, H; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Sideris, S; Yen, I; Yu, C; Heffron, TP 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 26: 534-9 (2016)
- Chen, Z; Wang, X; Zhu, W; Cao, X; Tong, L; Li, H; Xie, H; Xu, Y; Tan, S; Kuang, D; Ding, J; Qian, X Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. J Med Chem 54: 3732-45 (2011)
- Gaudreau, P; Boulanger, L; Abribat, T Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem 35: 1864-9 (1992)
- Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
- Emmitte, KA; Wilson, BJ; Baum, EW; Emerson, HK; Kuntz, KW; Nailor, KE; Salovich, JM; Smith, SC; Cheung, M; Gerding, RM; Stevens, KL; Uehling, DE; Mook, RA; Moorthy, GS; Dickerson, SH; Hassell, AM; Leesnitzer, MA; Shewchuk, LM; Groy, A; Rowand, JL; Anderson, K; Atkins, CL; Yang, J; Sabbatini, P; Kumar, R Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). Bioorg Med Chem Lett 19: 1004-8 (2009)
- Chen, X; Liu, L; Liu, P; Chen, Y; Lin, D; Yan, H; Yan, Q; Wang, Y; Qiu, Y; Fang, B; Huang, H; Qian, J; Zhao, Y; Du, Z; Zhang, Q; Li, X; Zheng, X; Liu, Z Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma. J Med Chem 65: 5374-5391 (2022)
- Starzec, A; Miteva, MA; Ladam, P; Villoutreix, BO; Perret, GY Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening. Bioorg Med Chem 22: 4042-8 (2014)
- Hanan, EJ; Eigenbrot, C; Bryan, MC; Burdick, DJ; Chan, BK; Chen, Y; Dotson, J; Heald, RA; Jackson, PS; La, H; Lainchbury, MD; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Seward, EM; Sideris, S; Tam, C; Wang, S; Yeap, SK; Yen, I; Yin, J; Yu, C; Zilberleyb, I; Heffron, TP Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem 57: 10176-91 (2014)
- Li, R; Pourpak, A; Morris, SW Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52: 4981-5004 (2010)
- Jaen, JC; Laborde, E; Bucsh, RA; Caprathe, BW; Sorenson, RJ; Fergus, J; Spiegel, K; Marks, J; Dickerson, MR; Davis, RE Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor. J Med Chem 38: 4439-45 (1995)
- Copp, BR; Fairchild, CR; Cornell, L; Casazza, AM; Robinson, S; Ireland, CM Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent. J Med Chem 41: 3909-11 (1998)
- Horbert, R; Pinchuk, B; Johannes, E; Schlosser, J; Schmidt, D; Cappel, D; Totzke, F; Schächtele, C; Peifer, C Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorß (PDGF-Rß) guided by water thermodynamics. J Med Chem 58: 170-82 (2015)
- Palmer, BD; Smaill, JB; Boyd, M; Boschelli, DH; Doherty, AM; Hamby, JM; Khatana, SS; Kramer, JB; Kraker, AJ; Panek, RL; Lu, GH; Dahring, TK; Winters, RT; Showalter, HD; Denny, WA Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem 41: 5457-65 (1998)
- Palmer, BD; Kraker, AJ; Hartl, BG; Panopoulos, AD; Panek, RL; Batley, BL; Lu, GH; Trumpp-Kallmeyer, S; Hollis Showalter, HD; Denny, WA Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem 42: 2373-82 (1999)
- Lüth, A; Löwe, W Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem 43: 1478-88 (2008)
- Norman, BH; McDermott, JS Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. J Med Chem 60: 66-88 (2017)
- Mahboobi, S; Teller, S; Pongratz, H; Hufsky, H; Sellmer, A; Botzki, A; Uecker, A; Beckers, T; Baasner, S; Schachtele, C; Uberall, F; Kassack, MU; Dove, S; Bohmer, FD Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem 45: 1002-18 (2002)
- Shvartsbart, A; Roach, JJ; Witten, MR; Koblish, H; Harris, JJ; Covington, M; Hess, R; Lin, L; Frascella, M; Truong, L; Leffet, L; Conlen, P; Beshad, E; Klabe, R; Katiyar, K; Kaldon, L; Young-Sciame, R; He, X; Petusky, S; Chen, KJ; Horsey, A; Lei, HT; Epling, LB; Deller, MC; Vechorkin, O; Yao, W Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3. J Med Chem 65: 15433-15442 (2022)
- Fairhurst, RA; Knoepfel, T; Buschmann, N; Leblanc, C; Mah, R; Todorov, M; Nimsgern, P; Ripoche, S; Niklaus, M; Warin, N; Luu, VH; Madoerin, M; Wirth, J; Graus-Porta, D; Weiss, A; Kiffe, M; Wartmann, M; Kinyamu-Akunda, J; Sterker, D; Stamm, C; Adler, F; Buhles, A; Schadt, H; Couttet, P; Blank, J; Galuba, I; Trappe, J; Voshol, J; Ostermann, N; Zou, C; Berghausen, J; Del Rio Espinola, A; Jahnke, W; Furet, P Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem 63: 12542-12573 (2020)
- Ducray, R; Simpson, I; Jung, FH; Nissink, JW; Kenny, PW; Fitzek, M; Walker, GE; Ward, LT; Hudson, K Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. Bioorg Med Chem Lett 21: 4698-701 (2011)
- Gundla, R; Kazemi, R; Sanam, R; Muttineni, R; Sarma, JA; Dayam, R; Neamati, N Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. J Med Chem 51: 3367-77 (2008)
- Weiss, MM; Harmange, JC; Polverino, AJ; Bauer, D; Berry, L; Berry, V; Borg, G; Bready, J; Chen, D; Choquette, D; Coxon, A; DeMelfi, T; Doerr, N; Estrada, J; Flynn, J; Graceffa, RF; Harriman, SP; Kaufman, S; La, DS; Long, A; Neervannan, S; Patel, VF; Potashman, M; Regal, K; Roveto, PM; Schrag, ML; Starnes, C; Tasker, A; Teffera, Y; Whittington, DA; Zanon, R Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J Med Chem 51: 1668-80 (2008)
- Hamed, MM; Darwish, SS; Herrmann, J; Abadi, AH; Engel, M First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-¿B Activity As Novel Anticancer Agents. J Med Chem 60: 2853-2868 (2017)
- Wang, L; Zhou, L; Reille-Seroussi, M; Gagey-Eilstein, N; Broussy, S; Zhang, T; Ji, L; Vidal, M; Liu, WQ Identification of Peptidic Antagonists of Vascular Endothelial Growth Factor Receptor 1 by Scanning the Binding Epitopes of Its Ligands. J Med Chem 60: 6598-6606 (2017)
- Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.
- Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Johnson, PD; Kettle, JG; Klinowska, T; Leach, AG; Morgentin, R; Pass, M; Ogilvie, DJ; Olivier, A; Warin, N; Williams, EJ Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorg Med Chem Lett 16: 1633-7 (2006)
- Wittman, MD; Balasubramanian, B; Stoffan, K; Velaparthi, U; Liu, P; Krishnanathan, S; Carboni, J; Li, A; Greer, A; Attar, R; Gottardis, M; Chang, C; Jacobson, B; Sun, Y; Hansel, S; Zoeckler, M; Vyas, DM Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg Med Chem Lett 17: 974-7 (2007)
- Wilson, EA; Russu, WA; Shallal, HM Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor. Bioorg Med Chem Lett 28: 1781-1784 (2018)
- Engel, J; Smith, S; Lategahn, J; Tumbrink, HL; Goebel, L; Becker, C; Hennes, E; Keul, M; Unger, A; Müller, H; Baumann, M; Schultz-Fademrecht, C; Günther, G; Hengstler, JG; Rauh, D Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. J Med Chem 60: 7725-7744 (2017)
- Yu, H; Wang, Z; Zhang, L; Zhang, J; Huang, Q The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Chem Biol Drug Des 69: 204-11 (2007)
- Smith, L; Piatnitski, EL; Kiselyov, AS; Ouyang, X; Chen, X; Burdzovic-Wizemann, S; Xu, Y; Pan, W; Chen, X; Wang, Y; Rosler, RL; Patel, SN; Chiang, HH; Milligan, DL; Columbus, J; Wong, WC; Doody, JF; Hadari, YR Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors. Bioorg Med Chem Lett 16: 1643-6 (2006)
- Tolkatchev, D; Vinogradova, A; Ni, F Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett 15: 5120-3 (2005)
- Wissner, A; Overbeek, E; Reich, MF; Floyd, MB; Johnson, BD; Mamuya, N; Rosfjord, EC; Discafani, C; Davis, R; Shi, X; Rabindran, SK; Gruber, BC; Ye, F; Hallett, WA; Nilakantan, R; Shen, R; Wang, YF; Greenberger, LM; Tsou, HR Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 46: 49-63 (2002)
- Lu, Y; Mao, F; Li, X; Zheng, X; Wang, M; Xu, Q; Zhu, J; Li, J Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRa) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). J Med Chem 60: 5099-5119 (2017)
- Sendzik, M; Janc, JW; Cabuslay, R; Honigberg, L; Mackman, RL; Magill, C; Squires, N; Waldeck, N Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth. Bioorg Med Chem Lett 14: 3181-4 (2004)
- Li, X; Guise, CP; Taghipouran, R; Yosaatmadja, Y; Ashoorzadeh, A; Paik, WK; Squire, CJ; Jiang, S; Luo, J; Xu, Y; Tu, ZC; Lu, X; Ren, X; Patterson, AV; Smaill, JB; Ding, K 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem 135: 531-543 (2017)
- La Motta, C; Sartini, S; Tuccinardi, T; Nerini, E; Da Settimo, F; Martinelli, A Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. J Med Chem 52: 964-75 (2009)
- Wan, G; Feng, Z; Zhang, Q; Li, X; Ran, K; Feng, H; Luo, T; Zhou, S; Su, C; Wei, W; Wang, N; Gao, C; Zhao, L; Yu, L Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. J Med Chem 65: 16541-16569 (2022)
- Wittlinger, F; Heppner, DE; To, C; Günther, M; Shin, BH; Rana, JK; Schmoker, AM; Beyett, TS; Berger, LM; Berger, BT; Bauer, N; Vasta, JD; Corona, CR; Robers, MB; Knapp, S; Jänne, PA; Eck, MJ; Laufer, SA Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. J Med Chem 65: 1370-1383 (2022)
- Potashman, MH; Bready, J; Coxon, A; Demelfi, TM; Dipietro, L; Doerr, N; Elbaum, D; Estrada, J; Gallant, P; Germain, J; Gu, Y; Harmange, JC; Kaufman, SA; Kendall, R; Kim, JL; Kumar, GN; Long, AM; Neervannan, S; Patel, VF; Polverino, A; Rose, P; Plas, SV; Whittington, D; Zanon, R; Zhao, H Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors. J Med Chem 50: 4351-4373 (2007)
- Zhou, F; Zhang, L; Jin, Y; Liu, W; Cheng, P; He, X; Xie, J; Shen, S; Lei, J; Ji, H; Hu, Y; Liu, Y; Cui, Y; Lv, Q; Lan, J Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors. Bioorg Med Chem Lett 28: 1257-1261 (2018)
- Zhou, W; Liu, X; Tu, Z; Zhang, L; Ku, X; Bai, F; Zhao, Z; Xu, Y; Ding, K; Li, H Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. J Med Chem 56: 7821-37 (2013)
- Peng, FW; Wu, TT; Ren, ZW; Xue, JY; Shi, L Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase. Bioorg Med Chem Lett 25: 5137-41 (2015)
- Salerno, S; Marini, AM; Fornaciari, G; Simorini, F; La Motta, C; Taliani, S; Sartini, S; Da Settimo, F; García-Argáez, AN; Gia, O; Cosconati, S; Novellino, E; D'Ocon, P; Fioravanti, A; Orlandi, P; Bocci, G; Dalla Via, L Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. Eur J Med Chem 103: 29-43 (2015)
- Mayer, SC; Banker, AL; Boschelli, F; Di, L; Johnson, M; Kenny, CH; Krishnamurthy, G; Kutterer, K; Moy, F; Petusky, S; Ravi, M; Tkach, D; Tsou, HR; Xu, W Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg Med Chem Lett 18: 3641-5 (2008)
- Mahboobi, S; Uecker, A; Sellmer, A; Cénac, C; Höcher, H; Pongratz, H; Eichhorn, E; Hufsky, H; Trümpler, A; Sicker, M; Heidel, F; Fischer, T; Stocking, C; Elz, S; Böhmer, FD; Dove, S Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 49: 3101-15 (2006)
- Zhu, YF; Wang, XC; Connors, P; Wilcoxen, K; Gao, Y; Gross, R; Strack, N; Gross, T; McCarthy, JR; Xie, Q; Ling, N; Chen, C Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. Bioorg Med Chem Lett 13: 1931-4 (2003)
- Chen, L; Fu, W; Zheng, L; Liu, Z; Liang, G Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. J Med Chem 61: 4290-4300 (2018)
- BurkeJr., TR; Li, ZH; Bolen, JB; Marquez, VE Structural influences of styryl-based inhibitors on epidermal growth factor receptor and p56lck tyrosine-specific protein kinases. Bioorg Med Chem Lett 1: 165-168 (1991)
- Song, Z; Jin, Y; Ge, Y; Wang, C; Zhang, J; Tang, Z; Peng, J; Liu, K; Li, Y; Ma, X Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. Bioorg Med Chem 24: 5505-5512 (2016)
- Kuo, GH; Wang, A; Emanuel, S; Deangelis, A; Zhang, R; Connolly, PJ; Murray, WV; Gruninger, RH; Sechler, J; Fuentes-Pesquera, A; Johnson, D; Middleton, SA; Jolliffe, L; Chen, X Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 48: 1886-900 (2005)
- Larroque, AL; Peori, B; Williams, C; Fang, YQ; Qiu, Q; Rachid, Z; Jean-Claude, BJ Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chem Biol Drug Des 71: 374-9 (2008)
- Larsen, CA; Bisson, WH; Dashwood, RH Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. J Med Chem 52: 6543-5 (2009)
- Tymecka, D; Puszko, AK; Lipiński, PFJ; Fedorczyk, B; Wilenska, B; Sura, K; Perret, GY; Misicka, A Branched pentapeptides as potent inhibitors of the vascular endothelial growth factor 165 binding to Neuropilin-1: Design, synthesis and biological activity. Eur J Med Chem 158: 453-462 (2018)
- Hou, J; Wan, S; Wang, G; Zhang, T; Li, Z; Tian, Y; Yu, Y; Wu, X; Zhang, J Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. Eur J Med Chem 118: 276-89 (2016)
- Hu, S; Liu, Y; Ma, J; Ding, W; Chen, H; Jiang, H; Chen, H; Wei, S; Liu, Y; Jin, Q; Yuan, H; Yan, L Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors. J Med Chem 66: 8858-8875 (2023)
- Zhong, Z; Zhong, Z; Shi, L; Shi, L; Fu, T; Fu, T; Huang, J; Huang, J; Pan, Z; Pan, Z Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma. J Med Chem 65: 7278-7295 (2022)
- Yao, W; Zhuo, J; Burns, DM; Xu, M; Zhang, C; Li, YL; Qian, DQ; He, C; Weng, L; Shi, E; Lin, Q; Agrios, C; Burn, TC; Caulder, E; Covington, MB; Fridman, JS; Friedman, S; Katiyar, K; Hollis, G; Li, Y; Liu, C; Liu, X; Marando, CA; Newton, R; Pan, M; Scherle, P; Taylor, N; Vaddi, K; Wasserman, ZR; Wynn, R; Yeleswaram, S; Jalluri, R; Bower, M; Zhou, BB; Metcalf, B Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. J Med Chem 50: 603-6 (2007)
- Yan, Q; Chen, Y; Tang, B; Xiao, Q; Qu, R; Tong, L; Liu, J; Ding, J; Chen, Y; Ding, N; Tan, W; Xie, H; Li, Y Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. Eur J Med Chem 152: 298-306 (2018)
- Cheng, H; Chang, Y; Zhang, L; Luo, J; Tu, Z; Lu, X; Zhang, Q; Lu, J; Ren, X; Ding, K Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. J Med Chem 57: 2692-703 (2014)
- Pandey, A; Volkots, DL; Seroogy, JM; Rose, JW; Yu, JC; Lambing, JL; Hutchaleelaha, A; Hollenbach, SJ; Abe, K; Giese, NA; Scarborough, RM Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 45: 3772-93 (2002)
- KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
- Miller, LM; Mayer, SC; Berger, DM; Boschelli, DH; Boschelli, F; Di, L; Du, X; Dutia, M; Floyd, MB; Johnson, M; Kenny, CH; Krishnamurthy, G; Moy, F; Petusky, S; Tkach, D; Torres, N; Wu, B; Xu, W Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg Med Chem Lett 19: 62-6 (2009)
- Antonello, A; Tarozzi, A; Morroni, F; Cavalli, A; Rosini, M; Hrelia, P; Bolognesi, ML; Melchiorre, C Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J Med Chem 49: 6642-5 (2006)
- Mulvihill, MJ; Ji, QS; Coate, HR; Cooke, A; Dong, H; Feng, L; Foreman, K; Rosenfeld-Franklin, M; Honda, A; Mak, G; Mulvihill, KM; Nigro, AI; O'Connor, M; Pirrit, C; Steinig, AG; Siu, K; Stolz, KM; Sun, Y; Tavares, PA; Yao, Y; Gibson, NW Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem 16: 1359-75 (2008)
- Jin, Q; Zhang, D; Gao, M; Jiang, C; Zhang, J Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma. Bioorg Med Chem 29: (2021)
- Zhu, ZW; Shi, L; Ruan, XM; Yang, Y; Li, HQ; Xu, SP; Zhu, HL Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. J Enzyme Inhib Med Chem 26: 37-45 (2011)
- Garofalo, A; Farce, A; Ravez, S; Lemoine, A; Six, P; Chavatte, P; Goossens, L; Depreux, P Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 55: 1189-204 (2012)
- Kuo, GH; Prouty, C; Wang, A; Emanuel, S; Deangelis, A; Zhang, Y; Song, F; Beall, L; Connolly, PJ; Karnachi, P; Chen, X; Gruninger, RH; Sechler, J; Fuentes-Pesquera, A; Middleton, SA; Jolliffe, L; Murray, WV Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 48: 4892-909 (2005)
- Li, DD; Lv, PC; Zhang, H; Zhang, HJ; Hou, YP; Liu, K; Ye, YH; Zhu, HL The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem 19: 5012-22 (2011)
- Gazit, A; App, H; McMahon, G; Chen, J; Levitzki, A; Bohmer, FD Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 39: 2170-7 (1996)
- Hudkins, RL; Becknell, NC; Zulli, AL; Underiner, TL; Angeles, TS; Aimone, LD; Albom, MS; Chang, H; Miknyoczki, SJ; Hunter, K; Jones-Bolin, S; Zhao, H; Bacon, ER; Mallamo, JP; Ator, MA; Ruggeri, BA Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c J Med Chem 55: 903-13 (2012)
- Glunz, PW; Zhang, X; Zou, Y; Delucca, I; Nirschl, AH; Cheng, X; Weigelt, CA; Cheney, DL; Wei, A; Anumula, R; Luettgen, JM; Rendina, AR; Harpel, M; Luo, G; Knabb, R; Wong, PC; Wexler, RR; Priestley, ES Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors. Bioorg Med Chem Lett 23: 5244-8 (2013)
- Wissner, A; Floyd, MB; Johnson, BD; Fraser, H; Ingalls, C; Nittoli, T; Dushin, RG; Discafani, C; Nilakantan, R; Marini, J; Ravi, M; Cheung, K; Tan, X; Musto, S; Annable, T; Siegel, MM; Loganzo, F 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J Med Chem 48: 7560-81 (2005)
- Bell, IM; Stirdivant, SM; Ahern, J; Culberson, JC; Darke, PL; Dinsmore, CJ; Drakas, RA; Gallicchio, SN; Graham, SL; Heimbrook, DC; Hall, DL; Hua, J; Kett, NR; Kim, AS; Kornienko, M; Kuo, LC; Munshi, SK; Quigley, AG; Reid, JC; Trotter, BW; Waxman, LH; Williams, TM; Zartman, CB Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. Biochemistry 44: 9430-40 (2005)
- Orcajo-Rincón, L; Ortega-Gutiérrez, S; Serrano, P; Torrecillas, IR; Wüthrich, K; Campillo, M; Pardo, L; Viso, A; Benhamú, B; López-Rodríguez, ML Development of non-peptide ligands of growth factor receptor-bound protein 2-SRC homology 2 domain using molecular modeling and NMR spectroscopy. J Med Chem 54: 1096-100 (2011)
- Zeng, Q; Wang, J; Cheng, Z; Chen, K; Johnström, P; Varnäs, K; Li, DY; Yang, ZF; Zhang, X Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem 58: 8200-15 (2015)
- Liu, X; Xie, H; Luo, C; Tong, L; Wang, Y; Peng, T; Ding, J; Jiang, H; Li, H Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J Med Chem 53: 2661-5 (2010)
- Yamani, A; Zdżalik-Bielecka, D; Lipner, J; Stańczak, A; Piórkowska, N; Stańczak, PS; Olejkowska, P; Hucz-Kalitowska, J; Magdycz, M; Dzwonek, K; Dubiel, K; Lamparska-Przybysz, M; Popiel, D; Pieczykolan, J; Wieczorek, M Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3). Eur J Med Chem 210: (2021)
- Wang, C; Wang, X; Huang, Z; Wang, T; Nie, Y; Yang, S; Xiang, R; Fan, Y Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. Eur J Med Chem 237: (2022)
- Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
- Chen, C; Zhu, YF; Liu, XJ; Lu, ZX; Xie, Q; Ling, N Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. J Med Chem 44: 4001-10 (2001)
- Serrao, E; Debnath, B; Otake, H; Kuang, Y; Christ, F; Debyser, Z; Neamati, N Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. J Med Chem 56: 2311-22 (2013)
- Cho, EH; Shin, HJ; Ki, MH; Kwon, HS; Lee, JW; Joo, JH; Lee, KK; Kim, JM; Park, YB; Kang, SH; Cho, HM; Kim, HT; Ahn, SK; Hong, SP; Kim, SH Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof US Patent US10844062 (2020)
- Ward, RA; Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Colclough, N; Chorley, CG; Chuaqui, C; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Hill, GB; Grist, M; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Waring, MJ Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J Med Chem 56: 7025-48 (2013)
- Shen, J; Zhang, T; Zhu, SJ; Sun, M; Tong, L; Lai, M; Zhang, R; Xu, W; Wu, R; Ding, J; Yun, CH; Xie, H; Lu, X; Ding, K Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR J Med Chem 62: 7302-7308 (2019)
- Lin, R; Johnson, SG; Connolly, PJ; Wetter, SK; Binnun, E; Hughes, TV; Murray, WV; Pandey, NB; Moreno-Mazza, SJ; Adams, M; Fuentes-Pesquera, AR; Middleton, SA Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Bioorg Med Chem Lett 19: 2333-7 (2009)
- Engen, W; O'Brien, TE; Kelly, B; Do, J; Rillera, L; Stapleton, LK; Youngren, JF; Anderson, MO Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R). Bioorg Med Chem 18: 5995-6005 (2010)
- Kottirsch, G; Koch, G; Feifel, R; Neumann, U Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem 45: 2289-93 (2002)
- Fevig, JM; Buriak, J; Cacciola, J; Alexander, RS; Kettner, CA; Knabb, RM; Pruitt, JR; Weber, PC; Wexler, RR Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. Bioorg Med Chem Lett 8: 301-6 (1999)
- AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
- Romagnoli, R; Prencipe, F; Oliva, P; Baraldi, S; Baraldi, PG; Schiaffino Ortega, S; Chayah, M; Kimatrai Salvador, M; Lopez-Cara, LC; Brancale, A; Ferla, S; Hamel, E; Ronca, R; Bortolozzi, R; Mariotto, E; Mattiuzzo, E; Viola, G Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. J Med Chem 62: 1274-1290 (2019)
- Ji, X; Peng, T; Zhang, X; Li, J; Yang, W; Tong, L; Qu, R; Jiang, H; Ding, J; Xie, H; Liu, H Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Bioorg Med Chem 22: 2366-78 (2014)
- Grabowska, K; Puszko, AK; Lipinski, PFJ; Laskowska, AK; Wilenska, B; Witkowska, E; Misicka, A Design, synthesis and in vitro biological evaluation of a small cyclic peptide as inhibitor of vascular endothelial growth factor binding to neuropilin-1. Bioorg Med Chem Lett 26: 2843-2846 (2016)
- Chang, S; Zhang, L; Xu, S; Luo, J; Lu, X; Zhang, Z; Xu, T; Liu, Y; Tu, Z; Xu, Y; Ren, X; Geng, M; Ding, J; Pei, D; Ding, K Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine7¿°¿ methionine7¿° mutant. J Med Chem 55: 2711-23 (2012)
- Pisaneschi, F; Nguyen, QD; Shamsaei, E; Glaser, M; Robins, E; Kaliszczak, M; Smith, G; Spivey, AC; Aboagye, EO Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation. Bioorg Med Chem 18: 6634-45 (2010)
- Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.
- Murphy, PV; Pitt, N; O'Brien, A; Enright, PM; Dunne, A; Wilson, SJ; Duane, RM; O'Boyle, KM Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library. Bioorg Med Chem Lett 12: 3287-90 (2002)
- Goncalves, V; Gautier, B; Regazzetti, A; Coric, P; Bouaziz, S; Garbay, C; Vidal, M; Inguimbert, N On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloaddition. Bioorg Med Chem Lett 17: 5590-4 (2007)
- Tsou, HR; Overbeek-Klumpers, EG; Hallett, WA; Reich, MF; Floyd, MB; Johnson, BD; Michalak, RS; Nilakantan, R; Discafani, C; Golas, J; Rabindran, SK; Shen, R; Shi, X; Wang, YF; Upeslacis, J; Wissner, A Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48: 1107-31 (2005)
- Cha, MY; Lee, KO; Kang, SJ; Jung, YH; Song, JY; Choi, KJ; Byun, JY; Lee, HJ; Lee, GS; Park, SB; Kim, MS Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. J Med Chem 55: 2846-57 (2012)
- Ying, S; Du, X; Fu, W; Yun, D; Chen, L; Cai, Y; Xu, Q; Wu, J; Li, W; Liang, G Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer. Eur J Med Chem 127: 885-899 (2017)
- Cai, ZW; Zhang, Y; Borzilleri, RM; Qian, L; Barbosa, S; Wei, D; Zheng, X; Wu, L; Fan, J; Shi, Z; Wautlet, BS; Mortillo, S; Jeyaseelan, R; Kukral, DW; Kamath, A; Marathe, P; D'Arienzo, C; Derbin, G; Barrish, JC; Robl, JA; Hunt, JT; Lombardo, LJ; Fargnoli, J; Bhide, RS Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215 J Med Chem 51: 1976-80 (2008)
- Wissner, A; Berger, DM; Boschelli, DH; Floyd, MB; Greenberger, LM; Gruber, BC; Johnson, BD; Mamuya, N; Nilakantan, R; Reich, MF; Shen, R; Tsou, HR; Upeslacis, E; Wang, YF; Wu, B; Ye, F; Zhang, N 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem 43: 3244-56 (2000)
- Chen, H; Lai, M; Zhang, T; Chen, Y; Tong, L; Zhu, S; Zhou, Y; Ren, X; Ding, J; Xie, H; Lu, X; Ding, K Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem 65: 6840-6858 (2022)
- Rachid, Z; Macphee, M; Williams, C; Todorova, M; Jean-Claude, BJ Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg Med Chem Lett 19: 5505-9 (2009)
- Zhang, X; Peng, T; Ji, X; Li, J; Tong, L; Li, Z; Yang, W; Xu, Y; Li, M; Ding, J; Jiang, H; Xie, H; Liu, H Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorg Med Chem 21: 7988-98 (2013)
- Patnaik, S; Stevens, KL; Gerding, R; Deanda, F; Shotwell, JB; Tang, J; Hamajima, T; Nakamura, H; Leesnitzer, MA; Hassell, AM; Shewchuck, LM; Kumar, R; Lei, H; Chamberlain, SD Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg Med Chem Lett 19: 3136-40 (2009)
- Lin, SY; Chang Hsu, Y; Peng, YH; Ke, YY; Lin, WH; Sun, HY; Shiao, HY; Kuo, FM; Chen, PY; Lien, TW; Chen, CH; Chu, CY; Wang, SY; Yeh, KC; Chen, CP; Hsu, TA; Wu, SY; Yeh, TK; Chen, CT; Hsieh, HP Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem 62: 10108-10123 (2019)
- Han, C; Huang, Z; Zheng, C; Wan, L; Zhang, L; Peng, S; Ding, K; Ji, H; Tian, J; Zhang, Y Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J Med Chem 56: 4738-48 (2013)
- Shaw, DE; Baig, F; Bruce, I; Chamoin, S; Collingwood, SP; Cross, S; Dayal, S; Drückes, P; Furet, P; Furminger, V; Haggart, D; Hussey, M; Konstantinova, I; Loren, JC; Molteni, V; Roberts, S; Reilly, J; Saunders, AM; Stringer, R; Sviridenko, L; Thomas, M; Thomson, CG; Tomlins, C; Wen, B; Yeh, V; Pearce, AC Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension. J Med Chem 59: 7901-14 (2016)
- Smaill, JB; Showalter, HD; Zhou, H; Bridges, AJ; McNamara, DJ; Fry, DW; Nelson, JM; Sherwood, V; Vincent, PW; Roberts, BJ; Elliott, WL; Denny, WA Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem 44: 429-40 (2001)
- Ott, GR; Asakawa, N; Liu, RQ; Covington, MB; Qian, M; Vaddi, K; Newton, RC; Trzaskos, JM; Christ, DD; Galya, L; Scholz, T; Marshall, W; Duan, JJ Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett 18: 1288-92 (2008)
- Voss, M; Sone, H; Chackalamannil, S; Ohkouchi, M Factor IXa inhibitors US Patent US8980916 (2015)
- Xu, J; Ali, A; Zhou, W; Gao, Y; Edmondson, SD; Mertz, E; Neelamkavil, SF; Liu, W; Sun, W; Shen, D; Harper, B; Zhu, C; Bara, T; Lim, Y; Yang, M Factor XIA inhibitors US Patent US10214512 (2019)
- Hicks, JD; McKittrick, BA; Whitehead, BR; Lombardo, M; Han, X; Taylor, JA; Chu, HD; So, S; Orth, P; Wu, Z Factor XIIa inhibitors US Patent US11014920 (2021)
- Ogawa, A; Edmondson, S; Erion, M; Neelamkavil, S; Guo, Z; Mal, R; He, J; Liu, W; Vande Bunte, EK Factor XIa inhibitors US Patent US9809545 (2017)
- Liu, W; Edmondson, SD; Guo, Z; Mertz, E; Ogawa, AK; So, S; Sun, W; Brockunier, LL; Ali, A; Kuang, R; Wu, H Factor Xla inhibitors US Patent US9783530 (2017)
- Chen, L; Chen, X; Wu, Y; Gai, D Transcription factor modulators US Patent US9133105 (2015)
- Groebke Zbinden, K; Banner, DW; Ackermann, J; Damppound39Arcy, A; Kirchhofer, D; Ji, YH; Tschopp, TB; Wallbaum, S; Weber, L Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett 15: 817-22 (2005)
- Zbinden, KG; Obst-Sander, U; Hilpert, K; Kuhne, H; Banner, DW; Bohm, HJ; Stahl, M; Ackermann, J; Alig, L; Weber, L; Wessel, HP; Riederer, MA; Tschopp, TB; Lave, T Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett 15: 5344-52 (2005)
- Ho, CY; Ludovici, DW; Maharoof, US; Mei, J; Sechler, JL; Tuman, RW; Strobel, ED; Andraka, L; Yen, HK; Leo, G; Li, J; Almond, H; Lu, H; DeVine, A; Tominovich, RM; Baker, J; Emanuel, S; Gruninger, RH; Middleton, SA; Johnson, DL; Galemmo, RA (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem 48: 8163-73 (2005)
- A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor.
- Asquith, CRM; Naegeli, KM; East, MP; Laitinen, T; Havener, TM; Wells, CI; Johnson, GL; Drewry, DH; Zuercher, WJ; Morris, DC Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. J Med Chem 62: 4772-4778 (2019)
- Wittman, MD; Carboni, JM; Yang, Z; Lee, FY; Antman, M; Attar, R; Balimane, P; Chang, C; Chen, C; Discenza, L; Frennesson, D; Gottardis, MM; Greer, A; Hurlburt, W; Johnson, W; Langley, DR; Li, A; Li, J; Liu, P; Mastalerz, H; Mathur, A; Menard, K; Patel, K; Sack, J; Sang, X; Saulnier, M; Smith, D; Stefanski, K; Trainor, G; Velaparthi, U; Zhang, G; Zimmermann, K; Vyas, DM Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem 52: 7360-3 (2009)
- Mohamed, FAM; Alakilli, SYM; El Azab, EF; Baawad, FAM; Shaaban, EIA; Alrub, HA; Hendawy, O; Gomaa, HAM; Bakr, AG; Abdelrahman, MH; Trembleau, L; Mohammed, AF; Youssif, BGM Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action. RSC Med Chem 14: 734-744 (2023)
- Li, Y; Yang, G; Zhang, J; Tang, P; Yang, C; Wang, G; Chen, J; Liu, J; Zhang, L; Ouyang, L Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem 64: 12022-12048 (2021)
- Mishani, E; Abourbeh, G; Jacobson, O; Dissoki, S; Ben Daniel, R; Rozen, Y; Shaul, M; Levitzki, A High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48: 5337-48 (2005)
- Cheng, X; Merz, KH; Vatter, S; Zeller, J; Muehlbeyer, S; Thommet, A; Christ, J; Wölfl, S; Eisenbrand, G Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. J Med Chem 60: 4949-4962 (2017)
- Rachid, Z; Brahimi, F; Qiu, Q; Williams, C; Hartley, JM; Hartley, JA; Jean-Claude, BJ Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. J Med Chem 50: 2605-8 (2007)
- Smith, L; Wong, WC; Kiselyov, AS; Burdzovic-Wizemann, S; Mao, Y; Xu, Y; Duncton, MA; Kim, K; Piatnitski, EL; Doody, JF; Wang, Y; Rosler, RL; Milligan, D; Columbus, J; Balagtas, C; Lee, SP; Konovalov, A; Hadari, YR Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 16: 5102-6 (2006)
- Barker, AJ; Gibson, KH; Grundy, W; Godfrey, AA; Barlow, JJ; Healy, MP; Woodburn, JR; Ashton, SE; Curry, BJ; Scarlett, L; Henthorn, L; Richards, L Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-4 (2001)
- Rode, HB; Sos, ML; Grütter, C; Heynck, S; Simard, JR; Rauh, D Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorg Med Chem 19: 429-39 (2011)
- Castelli, R; Giacomini, A; Anselmi, M; Bozza, N; Vacondio, F; Rivara, S; Matarazzo, S; Presta, M; Mor, M; Ronca, R Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. J Med Chem 59: 4651-63 (2016)
- Buckman, BO; Chou, YL; McCarrick, M; Liang, A; Lentz, D; Mohan, R; Morrissey, MM; Shaw, KJ; Trinh, L; Light, DR Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors. Bioorg Med Chem Lett 15: 2249-52 (2005)
- Xu, S; Xu, T; Zhang, L; Zhang, Z; Luo, J; Liu, Y; Lu, X; Tu, Z; Ren, X; Ding, K Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties. J Med Chem 56: 8803-13 (2013)
- Hao, Y; Wang, X; Zhang, T; Sun, D; Tong, Y; Xu, Y; Chen, H; Tong, L; Zhu, L; Zhao, Z; Chen, Z; Ding, J; Xie, H; Xu, Y; Li, H Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. J Med Chem 59: 7111-24 (2016)
- Degorce, SL; Boyd, S; Curwen, JO; Ducray, R; Halsall, CT; Jones, CD; Lach, F; Lenz, EM; Pass, M; Pass, S; Trigwell, C Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). J Med Chem 59: 4859-66 (2016)
- Matsuno, K; Ichimura, M; Nakajima, T; Tahara, K; Fujiwara, S; Kase, H; Ushiki, J; Giese, NA; Pandey, A; Scarborough, RM; Lokker, NA; Yu, JC; Irie, J; Tsukuda, E; Ide, S; Oda, S; Nomoto, Y Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. J Med Chem 45: 3057-66 (2002)
- Banerjee, R; Rachid, Z; McNamee, J; Jean-Claude, BJ Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 46: 5546-51 (2003)
- Smaill, JB; Gonzales, AJ; Spicer, JA; Lee, H; Reed, JE; Sexton, K; Althaus, IW; Zhu, T; Black, SL; Blaser, A; Denny, WA; Ellis, PA; Fakhoury, S; Harvey, PJ; Hook, K; McCarthy, FO; Palmer, BD; Rivault, F; Schlosser, K; Ellis, T; Thompson, AM; Trachet, E; Winters, RT; Tecle, H; Bridges, A Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. J Med Chem 59: 8103-24 (2016)
- Palmer, BD; Trumpp-Kallmeyer, S; Fry, DW; Nelson, JM; Showalter, HD; Denny, WA Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J Med Chem 40: 1519-29 (1997)
- Zhang, X; Glunz, P; Priestley, ES; Johnson, JA; Wurtz, NR; Ladziata, V Macrocyclic factor VIIa inhibitors US Patent US9174974 (2015)
- Wang, C; Corte, JR; Rossi, KA; Bozarth, JM; Wu, Y; Sheriff, S; Myers, JE; Luettgen, JM; Seiffert, DA; Wexler, RR; Quan, ML Macrocyclic factor XIa inhibitors. Bioorg Med Chem Lett 27: 4056-4060 (2017)
- Velaparthi, U; Wittman, M; Liu, P; Stoffan, K; Zimmermann, K; Sang, X; Carboni, J; Li, A; Attar, R; Gottardis, M; Greer, A; Chang, CY; Jacobsen, BL; Sack, JS; Sun, Y; Langley, DR; Balasubramanian, B; Vyas, D Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R). Bioorg Med Chem Lett 17: 2317-21 (2007)
- Yan, W; Wang, X; Dai, Y; Zhao, B; Yang, X; Fan, J; Gao, Y; Meng, F; Wang, Y; Luo, C; Ai, J; Geng, M; Duan, W Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. J Med Chem 59: 6690-708 (2016)
- Wittman, M; Carboni, J; Attar, R; Balasubramanian, B; Balimane, P; Brassil, P; Beaulieu, F; Chang, C; Clarke, W; Dell, J; Eummer, J; Frennesson, D; Gottardis, M; Greer, A; Hansel, S; Hurlburt, W; Jacobson, B; Krishnananthan, S; Lee, FY; Li, A; Lin, TA; Liu, P; Ouellet, C; Sang, X; Saulnier, MG; Stoffan, K; Sun, Y; Velaparthi, U; Wong, H; Yang, Z; Zimmermann, K; Zoeckler, M; Vyas, D Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 48: 5639-43 (2005)
- Li, Y; Liu, Y; Zhang, D; Chen, J; Yang, G; Tang, P; Yang, C; Liu, J; Zhang, J; Ouyang, L Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy. J Med Chem 66: 12069-12100 (2023)
- Heath, JA; Mehrotra, MM; Chi, S; Yu, JC; Hutchaleelaha, A; Hollenbach, SJ; Giese, NA; Scarborough, RM; Pandey, A Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor. Bioorg Med Chem Lett 14: 4867-72 (2004)
- Peng, YH; Shiao, HY; Tu, CH; Liu, PM; Hsu, JT; Amancha, PK; Wu, JS; Coumar, MS; Chen, CH; Wang, SY; Lin, WH; Sun, HY; Chao, YS; Lyu, PC; Hsieh, HP; Wu, SY Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. J Med Chem 56: 3889-903 (2013)
- Wang, GT; Mantei, RA; Hubbard, RD; Wilsbacher, JL; Zhang, Q; Tucker, L; Hu, X; Kovar, P; Johnson, EF; Osterling, DJ; Bouska, J; Wang, J; Davidsen, SK; Bell, RL; Sheppard, GS Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg Med Chem Lett 20: 6067-71 (2010)
- Rewcastle, GW; Bridges, AJ; Fry, DW; Rubin, JR; Denny, WA Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J Med Chem 40: 1820-6 (1997)
- Rewcastle, GW; Palmer, BD; Bridges, AJ; Showalter, HD; Sun, L; Nelson, J; McMichael, A; Kraker, AJ; Fry, DW; Denny, WA Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 39: 918-28 (1996)
- Hansen, TK; Ankersen, M; Hansen, BS; Raun, K; Nielsen, KK; Lau, J; Peschke, B; Lundt, BF; Thøgersen, H; Johansen, NL; Madsen, K; Andersen, PH Novel orally active growth hormone secretagogues. J Med Chem 41: 3705-14 (1998)
- Yang, L; Morriello, G; Prendergast, K; Cheng, K; Jacks, T; Chan, WW; Schleim, KD; Smith, RG; Patchett, AA Potent 3-spiropiperidine growth hormone secretagogues. Bioorg Med Chem Lett 8: 107-12 (1999)
- Ladziata, VU; Glunz, PW; Zou, Y; Zhang, X; Jiang, W; Jacutin-Porte, S; Cheney, DL; Wei, A; Luettgen, JM; Harper, TM; Wong, PC; Seiffert, D; Wexler, RR; Priestley, ES Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors. Bioorg Med Chem Lett 26: 5051-5057 (2016)
- Bar-Tana, J; Ben-Shoshan, S; Blum, J; Migron, Y; Hertz, R; Pill, J; Rose-Khan, G; Witte, EC Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids. J Med Chem 32: 2072-84 (1989)
- Barvian, MR; Panek, RL; Lu, GH; Kraker, AJ; Amar, A; Hartl, B; Hamby, JM; Showalter, HD 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase Bioorg Med Chem Lett 7: 2903-2908 (1997)
- Perspicace, E; Jouan-Hureaux, V; Ragno, R; Ballante, F; Sartini, S; La Motta, C; Da Settimo, F; Chen, B; Kirsch, G; Schneider, S; Faivre, B; Hesse, S Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). Eur J Med Chem 63: 765-81 (2013)
- Peifer, C; Selig, R; Kinkel, K; Ott, D; Totzke, F; Schächtele, C; Heidenreich, R; Röcken, M; Schollmeyer, D; Laufer, S Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. J Med Chem 51: 3814-24 (2008)
- Wang, DP; Liu, KL; Li, XY; Lu, GQ; Xue, WH; Qian, XH; Mohamed O, K; Meng, FH Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold. Eur J Med Chem 211: (2021)
- Harris, PA; Boloor, A; Cheung, M; Kumar, R; Crosby, RM; Davis-Ward, RG; Epperly, AH; Hinkle, KW; Hunter, RN; Johnson, JH; Knick, VB; Laudeman, CP; Luttrell, DK; Mook, RA; Nolte, RT; Rudolph, SK; Szewczyk, JR; Truesdale, AT; Veal, JM; Wang, L; Stafford, JA Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51: 4632-40 (2008)
- Bilodeau, MT; Balitza, AE; Koester, TJ; Manley, PJ; Rodman, LD; Buser-Doepner, C; Coll, KE; Fernandes, C; Gibbs, JB; Heimbrook, DC; Huckle, WR; Kohl, N; Lynch, JJ; Mao, X; McFall, RC; McLoughlin, D; Miller-Stein, CM; Rickert, KW; Sepp-Lorenzino, L; Shipman, JM; Subramanian, R; Thomas, KA; Wong, BK; Yu, S; Hartman, GD Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. J Med Chem 47: 6363-72 (2004)
- Grabowska, K; Puszko, AK; Lipinski, PF; Laskowska, AK; Wilenska, B; Witkowska, E; Perret, GY; Misicka, A Structure-activity relationship study of a small cyclic peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor interaction with Neuropilin-1. Bioorg Med Chem 25: 597-602 (2017)
- Gangjee, A; Zaware, N; Raghavan, S; Disch, BC; Thorpe, JE; Bastian, A; Ihnat, MA Synthesis and biological activity of 5-chloro-N4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. Bioorg Med Chem 21: 1857-64 (2013)
- Li, S; Guo, C; Sun, X; Li, Y; Zhao, H; Zhan, D; Lan, M; Tang, Y Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. Eur J Med Chem 49: 271-8 (2012)
- Smaill, JB; Palmer, BD; Rewcastle, GW; Denny, WA; McNamara, DJ; Dobrusin, EM; Bridges, AJ; Zhou, H; Showalter, HD; Winters, RT; Leopold, WR; Fry, DW; Nelson, JM; Slintak, V; Elliot, WL; Roberts, BJ; Vincent, PW; Patmore, SJ Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 42: 1803-15 (1999)
- Smaill, JB; Rewcastle, GW; Loo, JA; Greis, KD; Chan, OH; Reyner, EL; Lipka, E; Showalter, HD; Vincent, PW; Elliott, WL; Denny, WA Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 43: 1380-97 (2001)
- Mukherjee, A; Raychaudhuri, D; Sinha, BP; Kundu, B; Mitra, M; Paul, B; Bandopadhyay, P; Ganguly, D; Talukdar, A A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist. J Med Chem 63: 4776-4789 (2020)
- Czekaj, M; Klein, SI; Guertin, KR; Gardner, CJ; Zulli, AL; Pauls, HW; Spada, AP; Cheney, DL; Brown, KD; Colussi, DJ; Chu, V; Leadley, RJ; Dunwiddie, CT Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency. Bioorg Med Chem Lett 12: 1667-70 (2002)
- Corte, JR; Fang, T; Decicco, CP; Pinto, DJ; Rossi, KA; Hu, Z; Jeon, Y; Quan, ML; Smallheer, JM; Wang, Y; Yang, W Macrocycles as factor XIa inhibitors US Patent US9802939 (2017)
- ChEMBL_208097 (CHEMBL814453) Inhibition of Transforming growth factor beta-1 receptor (TbetaRI)
- ChEMBL_208098 (CHEMBL814454) Inhibition of Transforming growth factor beta-1 receptor (TbetaRI) autophosphorylation
- ChEMBL_305842 (CHEMBL829583) Stimulation of Transforming growth factor beta receptor I kinase in HepG2 cells
- ChEMBL_129905 (CHEMBL740149) In vitro inhibition of transforming growth factor- beta dependent luciferase growth in mouse fibroblasts (NIH 3T3)
- ChEMBL_208101 (CHEMBL814457) In vitro inhibitory activity against human Transforming growth factor beta-1 receptor kinase (TGF-beta RIK)
- ChEMBL_208100 (CHEMBL814456) Inhibition of human Transforming growth factor (TGF) beta-1 receptor (T204D mutation) autophosphorylation in Sf9 cells
- ChEMBL_123678 (CHEMBL728561) In vitro inhibition of transforming growth factor- beta dependent luciferase production in mink lung cells (p3TP Lux)
- ChEBML_158665 Inhibition of Platelet-derived growth factor receptor beta (PDGF beta-R)
- ChEMBL_158657 (CHEMBL763443) Inhibition of Platelet-derived growth factor receptor beta
- ChEMBL_158678 (CHEMBL766068) Inhibition of Platelet-derived growth factor receptor beta
- ChEMBL_158679 (CHEMBL766069) Inhibition of Platelet-derived growth factor receptor beta
- ChEMBL_158524 (CHEMBL768951) Inhibition of Platelet-derived growth factor receptor beta phosphorylation
- ChEMBL_305323 (CHEMBL833545) Inhibition of human platelet-derived growth factor receptor beta
- ChEBML_158518 Inhibitory concentration against platelet-derived growth factor receptor beta phosphorylation in CHO cells
- ChEMBL_306481 (CHEMBL874567) Inhibition of Platelet derived growth factor receptor beta autophosphorylation in CHO cells
- ChEBML_158654 Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells
- ChEMBL_158666 (CHEMBL764169) In vitro inhibition of Platelet-derived growth factor receptor beta expressed in baculovirus
- ChEMBL_158667 (CHEMBL766057) In vitro inhibition of Platelet-derived growth factor receptor beta expressed in baculovirus
- ChEMBL_158654 (CHEMBL763440) Inhibition of wild type Platelet-derived growth factor receptor beta phosphorylation in CHO cells
- ChEBML_63790 Antagonism towards Epidermal growth factor receptor
- ChEBML_66573 Inhibition of Epidermal growth factor receptor
- ChEBML_67063 Inhibition of Epidermal growth factor receptor
- ChEBML_67064 Inhibition of Epidermal growth factor receptor
- ChEBML_67065 Inhibition of Epidermal growth factor receptor
- ChEBML_67067 Inhibition of Epidermal growth factor receptor
- ChEBML_67204 Inhibition of Epidermal growth factor receptor
- ChEBML_67211 Inhibition of epidermal growth factor receptor
- ChEBML_221782 Inhibition of epidermal growth factor receptor (EGFR)
- ChEBML_225788 Inhibition of nerve growth factor receptor, trkA
- ChEBML_63595 Inhibit of epidermal growth factor receptor (EGFR)
- ChEBML_66904 Inhibition of the epidermal growth factor receptor.
- ChEBML_66906 Inhibition of epidermal growth factor receptor (EGFR)
- ChEBML_66907 Inhibition of epidermal growth factor receptor (EGFR)
- ChEBML_67058 Inhibitory activity against epidermal growth factor receptor
- ChEBML_67068 Inhibition of Epidermal growth factor receptor (EGFr)
- ChEBML_70637 Inhibition of Fibroblast growth factor receptor 2
- ChEBML_78745 Inhibition of human Epidermal growth factor receptor
- ChEMBL_305263 (CHEMBL832813) Inhibition of epidermal growth factor receptor
- ChEMBL_306181 (CHEMBL830975) Inhibition of Epidermal growth factor receptor
- ChEMBL_306396 (CHEMBL828737) Inhibition of Epidermal growth factor receptor
- ChEMBL_67049 (CHEMBL677887) Inhibition of Epidermal growth factor receptor
- ChEMBL_67054 (CHEMBL674103) Inhibition of Epidermal growth factor receptor
- ChEMBL_67208 (CHEMBL678293) Inhibition of Epidermal growth factor receptor
- ChEMBL_67211 (CHEMBL678296) Inhibition of epidermal growth factor receptor
- ChEMBL_67212 (CHEMBL678297) Inhibition of Epidermal growth factor receptor
- ChEMBL_67213 (CHEMBL677529) Inhibition of Epidermal growth factor receptor
- ChEMBL_67214 (CHEMBL677530) Inhibition of Epidermal growth factor receptor
- ChEMBL_67215 (CHEMBL677531) Selectivity against Epidermal growth factor receptor
- ChEMBL_70490 (CHEMBL676887) Inhibition of Fibroblast growth factor receptor
- ChEMBL_70491 (CHEMBL676888) Inhibition of Fibroblast growth factor receptor
- ChEMBL_70493 (CHEMBL676890) Inhibition of Fibroblast growth factor receptor
- ChEMBL_84064 (CHEMBL697832) Inhibition of Hepatocyte growth factor receptor
- ChEMBL_158513 (CHEMBL768940) Binding affinity against abl SH2 domain of Platelet-derived growth factor receptor beta in Sf9 insect cells
- ChEMBL_158651 (CHEMBL763437) Inhibition of platelet-derived growth factor receptor beta phosphorylation in MG63 cells in the absence of plasma
- ChEMBL_306667 (CHEMBL832268) In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasma
- ChEBML_158502 Inhibition of the platelet-derived growth factor receptor.
- ChEBML_213951 Inhibitory activity against Vascular endothelial growth factor receptor
- ChEBML_213959 Inhibition of vascular endothelial growth factor receptor 1
- ChEBML_213960 Inhibition of Vascular endothelial growth factor receptor 1
- ChEBML_213967 Inhibition of Vascular endothelial growth factor receptor 2
- ChEBML_213970 Inhibition of Vascular endothelial growth factor receptor 2
- ChEBML_214231 Inhibition of Vascular endothelial growth factor receptor 2
- ChEBML_214243 Inhibition of Vascular endothelial growth factor receptor 2
- ChEBML_214253 Inhibition of Vascular endothelial growth factor receptor 3
- ChEBML_63607 Inhibition of tyrosine kinase Epidermal growth factor receptor
- ChEBML_64439 Inhibition of epidermal growth factor receptor (EGF-R)
- ChEBML_66581 Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation
- ChEBML_67041 Inhibition of epidermal growth factor receptor (EGF-R)
- ChEBML_70625 Inhibitory activity against Fibroblast growth factor receptor 1
- ChEBML_88298 Inhibition of human epidermal growth factor receptor-2
- ChEBML_90397 Inhibition of Insulin-like growth factor I receptor
- ChEMBL_158490 (CHEMBL764769) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_158491 (CHEMBL764770) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_158494 (CHEMBL764773) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_158495 (CHEMBL765708) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_158496 (CHEMBL765709) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_158503 (CHEMBL765716) Inhibition of Platelet-derived growth factor receptor
- ChEMBL_213950 (CHEMBL811928) Inhibition of Vascular endothelial growth factor receptor
- ChEMBL_305210 (CHEMBL832463) Inhibition of Epidermal growth factor receptor 1
- ChEMBL_305211 (CHEMBL832464) Inhibition of Fibroblast growth factor receptor 2
- ChEMBL_305359 (CHEMBL832739) Inhibition of Platelet derived growth factor receptor
- ChEMBL_305858 (CHEMBL832718) Inhibition of human epidermal growth factor receptor
- ChEMBL_306570 (CHEMBL832087) Inhibition of Vascular endothelial growth factor receptor
- ChEMBL_63595 (CHEMBL675242) Inhibit of epidermal growth factor receptor (EGFR)
- ChEMBL_63755 (CHEMBL679943) Inhibition of Epidermal growth factor receptor autophosphorylation
- ChEMBL_63757 (CHEMBL679945) Inhibition of Epidermal growth factor receptor autophosphorylation
- ChEMBL_65256 (CHEMBL673947) Inhibition of epidermal growth factor receptor (EGFR)
- ChEMBL_66578 (CHEMBL683038) Inhibition of human Epidermal growth factor receptor
- ChEMBL_66579 (CHEMBL683039) Inhibition of human epidermal growth factor receptor
- ChEMBL_66582 (CHEMBL683042) Inhibition of human epidermal growth factor receptor
- ChEMBL_67055 (CHEMBL674104) Inhibition of Epidermal growth factor receptor autophosphorylation
- ChEMBL_67058 (CHEMBL674107) Inhibitory activity against epidermal growth factor receptor
- ChEMBL_70618 (CHEMBL678674) Inhibition of Fibroblast growth factor receptor 1
- ChEMBL_70628 (CHEMBL678684) Dissociation constant for Fibroblast growth factor 1
- ChEMBL_70638 (CHEMBL678694) Dissociation constant for Fibroblast growth factor 2
- ChEMBL_158652 (CHEMBL763438) Inhibition of platelet derived growth factor receptor beta phosphorylation in MG63 cells in the presence of human plasma
- ChEBML_214094 Inhibition of human vascular endothelial growth factor receptor 2
- ChEBML_214117 Inhibitory activity against Vascular endothelial growth factor receptor 2
- ChEBML_63617 Inhibition of Epidermal growth factor receptor autophosphorylation, 0.05-0.10
- ChEBML_66577 Inhibition of human Epidermal growth factor receptor, HER-1
- ChEBML_67205 Tested for inhibitory activity against Epidermal growth factor receptor
- ChEBML_72494 Inhibitory activity against Growth factor receptor bound protein 2
- ChEBML_88297 Inhibition of human epidermal growth factor receptor-2 autophosphorylation
- ChEBML_90282 Inhibition of human insulin-like growth factor I receptor
- ChEMBL_158502 (CHEMBL765715) Inhibition of the platelet-derived growth factor receptor.
- ChEMBL_158511 (CHEMBL764074) Inhibition of Platelet-derived growth factor receptor alpha
- ChEMBL_213947 (CHEMBL811925) Inhibition of Vascular endothelial growth factor receptor 3
- ChEMBL_213951 (CHEMBL811929) Inhibitory activity against Vascular endothelial growth factor receptor
- ChEMBL_213964 (CHEMBL811941) Inhibition of Vascular endothelial growth factor receptor 1
- ChEMBL_214113 (CHEMBL820699) Inhibition of Vascular endothelial growth factor receptor 2
- ChEMBL_214115 (CHEMBL820701) Inhibition of Vascular endothelial growth factor receptor 2
- ChEMBL_214240 (CHEMBL819558) Inhibition of Vascular endothelial growth factor receptor 2
- ChEMBL_214243 (CHEMBL820211) Inhibition of Vascular endothelial growth factor receptor 2
- ChEMBL_214250 (CHEMBL820849) Inhibition of Vascular endothelial growth factor receptor 3
- ChEMBL_305013 (CHEMBL829448) Inhibition of human fibroblast growth factor receptor 1
- ChEMBL_305182 (CHEMBL832771) Inhibition of platelet-derived growth factor receptor alpha
- ChEMBL_305183 (CHEMBL876146) Inhibition of vascular endothelial growth factor receptor 2
- ChEMBL_305253 (CHEMBL832663) Inhibition of human fibroblast growth factor receptor 1
- ChEMBL_305378 (CHEMBL832893) In vitro inhibition of Epidermal growth factor receptor
- ChEMBL_305535 (CHEMBL828555) Inhibition of vascular endothelial growth factor receptor 2
- ChEMBL_321229 (CHEMBL881229) Inhibitory activity against Fibroblast growth factor receptor 3
- ChEMBL_321279 (CHEMBL857667) Inhibitory concentration against platelet-derived growth factor receptor
- ChEMBL_582001 (CHEMBL1055738) Inhibition of IGF1R in growth factor-stimulated NHDF
- ChEMBL_63610 (CHEMBL676154) Inhibition of Epidermal growth factor receptor tyrosine kinase
- ChEMBL_63780 (CHEMBL677384) Inhibition of epidermal growth factor receptor kinase autophosphorylation
- ChEMBL_64439 (CHEMBL674014) Inhibition of epidermal growth factor receptor (EGF-R)
- ChEMBL_66585 (CHEMBL680016) Inhibition of Epidermal growth factor receptor, HER-1
- ChEMBL_66876 (CHEMBL676067) Inhibitory activity against epidermal growth factor receptor (EGFR)
- ChEMBL_67041 (CHEMBL677879) Inhibition of epidermal growth factor receptor (EGF-R)
- ChEMBL_67051 (CHEMBL677889) Inhibition of Epidermal growth factor receptor-dependent phosphorylation
- ChEMBL_70488 (CHEMBL676885) Inhibitory activity against fibroblast growth factor receptor (FGFr)
- ChEMBL_850923 (CHEMBL2156906) Inhibition of Platelet-derived growth factor subunit B
- ChEMBL_877987 (CHEMBL2189053) Inhibition of vascular endothelial growth factor receptor 2
- ChEMBL_90285 (CHEMBL697504) Inhibition of Insulin-like growth factor I receptor
- ChEMBL_90396 (CHEMBL698351) Inhibition of Insulin-like growth factor I receptor
- ChEBML_90404 Ability to displace Insulin-Like Growth Factor (IGF-I) from its binding to human insulin-like growth factor binding protein 3 (hIGFBP-3)
- ChEMBL_306777 (CHEMBL831532) In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells with 45% human plasma
- ChEBML_90403 Ability of compound to displace Insulin-Like Growth Factor (IGF-I) from its binding to Insulin-like growth factor binding protein 3 (IGFBP-3)
- ChEBML_90543 Ability of compound to displace Insulin-Like Growth Factor (IGF-I) from its binding to Insulin-like growth factor binding protein 5 (IGFBP-5)
- ChEMBL_158520 (CHEMBL768947) Test concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Platelet-derived growth factor receptor beta (PDGF RTK).
- ChEBML_63781 Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor
- ChEBML_70479 Inhibition of Fibroblast growth factor receptor in NIH 3T3 cells
- ChEMBL_152446 (CHEMBL761271) Inhibition of Platelet-derived growth factor receptor tyrosine kinase
- ChEMBL_154585 (CHEMBL761933) Inhibition of platelet-derived growth factor receptor (PDGF-R)
- ChEMBL_158492 (CHEMBL764771) Inhibition of Platelet-derived growth factor receptor-dependent phosphorylation
- ChEMBL_214107 (CHEMBL820693) Inhibition of human Vascular endothelial growth factor receptor 2
- ChEMBL_305115 (CHEMBL831583) Inhibition of human insulin-like growth factor I receptor
- ChEMBL_305462 (CHEMBL830958) Inhibitory concentration against growth factor receptor bound protein 2
- ChEMBL_305482 (CHEMBL830273) Inhibition of human epidermal growth factor receptor (HER-1)
- ChEMBL_305511 (CHEMBL831112) inhibitory activity against Vascular endothelial growth factor receptor 2
- ChEMBL_305656 (CHEMBL829514) Inhibition of Epidermal growth factor receptor in P19 cells
- ChEMBL_305679 (CHEMBL828051) Inhibition of human Vascular endothelial growth factor receptor 2
- ChEMBL_306103 (CHEMBL830878) Inhibitory concentration against Vascular endothelial growth factor receptor 2
- ChEMBL_312997 (CHEMBL873338) Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation
- ChEMBL_321286 (CHEMBL856815) Inhibitory activity against Platelet-derived growth factor receptor alpha
- ChEMBL_63617 (CHEMBL676161) Inhibition of Epidermal growth factor receptor autophosphorylation, 0.05-0.10
- ChEMBL_66577 (CHEMBL683037) Inhibition of human Epidermal growth factor receptor, HER-1
- ChEMBL_66897 (CHEMBL675521) Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase
- ChEMBL_66898 (CHEMBL675380) Inhibition of epidermal growth factor receptor (EGFr) tyrosine kinase
- ChEMBL_67042 (CHEMBL677880) In vitro inhibitory activity against epidermal growth factor receptor
- ChEMBL_67206 (CHEMBL678292) Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase
- ChEBML_210742 Inhibition of receptor Tyrosine kinase A, TrkA (nerve growth factor receptor)
- ChEBML_66896 Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cell membranes
- ChEBML_67061 Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity
- ChEMBL_213948 (CHEMBL811926) Inhibitory activity against vascular endothelial growth factor receptor 2 (FLK1)
- ChEMBL_213949 (CHEMBL811927) Inhibitory activity against vascular endothelial growth factor receptor 2 (FLK1)
- ChEMBL_214241 (CHEMBL819559) Inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2)
- ChEMBL_302139 (CHEMBL841763) Dissociation constant value against growth factor receptor bound protein 2
- ChEMBL_305356 (CHEMBL832736) Inhibition of epidermal growth factor receptor in cell-free assay
- ChEMBL_305416 (CHEMBL830909) Inhibition of epidermal growth factor receptor in cell-intact assay
- ChEMBL_305452 (CHEMBL830127) Inhibition of hepatocyte growth factor receptor in cell-intact assay
- ChEMBL_305774 (CHEMBL827963) In vitro inhibition of Vascular endothelial growth factor receptor 2
- ChEMBL_305880 (CHEMBL832743) Inhibition of Platelet-derived growth factor receptor in P19 cells
- ChEMBL_305999 (CHEMBL832673) Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity
- ChEMBL_321426 (CHEMBL881957) Inhibitory concentration against human Vascular endothelial growth factor receptor 2
- ChEMBL_63592 (CHEMBL675239) Inhibition of heparin-binding epidermal growth factor (HB-EGF) shedding
- ChEMBL_63781 (CHEMBL677385) Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor
- ChEMBL_66889 (CHEMBL675513) Inhibition of epidermal growth factor receptor tyrosine kinase (EGFR TK)
- ChEMBL_90405 (CHEMBL698360) Inhibitory activity against Insulin-like growth factor binding protein 3
- ChEMBL_158521 (CHEMBL768948) Concentration required for 50% inhibition against autophosphorylation of Platelet-derived growth factor receptor beta in intact cells using a two site ELISA
- ChEMBL_158653 (CHEMBL763439) Inhibition of platelet-derived growth factor receptor beta phosphorylation was measured in intact cells using a two-site enzyme linked immunosorbent assay (ELISA)
- ChEBML_214091 Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP
- ChEBML_214114 Inhibition of vascular endothelial growth factor receptor 2 autophosphorylation in intact cells
- ChEBML_66717 Inhibition of the epidermal growth factor receptor expressed in A431 cell line
- ChEBML_72354 Binding affinity against Growth factor receptor bound protein 2 using ELISA assay
- ChEMBL_105473 (CHEMBL708303) Inhibition of Mast/stem cell growth factor receptor (c-kit) autophosphorylation
- ChEMBL_105474 (CHEMBL708304) Inhibition of Mast/stem cell growth factor receptor (c-kit) autophosphorylation
- ChEMBL_105477 (CHEMBL708307) Inhibition of Mast/stem cell growth factor receptor (c-Kit kinase)
- ChEMBL_158357 (CHEMBL770468) Inhibitory concentration of compound against mouse Platelet-derived growth factor receptor
- ChEMBL_210741 (CHEMBL818317) Inhibition of receptor Tyrosine kinase A, TrkA (nerve growth factor receptor)
- ChEMBL_213973 (CHEMBL812622) Inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) autophosphorylation
- ChEMBL_302160 (CHEMBL829228) Apparent dissociation constant for human growth factor receptor bound protein 2
- ChEMBL_305501 (CHEMBL831103) Inhibition of fibroblast growth factor receptor 2 in cell-intact assay
- ChEMBL_305591 (CHEMBL828038) Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1)
- ChEMBL_305649 (CHEMBL829507) Inhibition of human vascular endothelial growth factor receptor 2 (VEGFR-2)
- ChEMBL_305849 (CHEMBL829589) Inhibition of human vascular endothelial growth factor receptor 2 kinase activity
- ChEMBL_313008 (CHEMBL874202) Inhibition of human epidermal growth factor receptor-2 (HER-2) autophosphorylation
- ChEMBL_63613 (CHEMBL676157) Inhibition of epidermal growth factor receptor (EGF-R) in A431 cells.
- ChEMBL_66597 (CHEMBL680028) Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor
- ChEMBL_66886 (CHEMBL675510) Inhibition of Epidermal growth factor receptor mediated mitogenesis of NIH3T3 cells
- ChEMBL_67044 (CHEMBL677882) In vitro inhibition of Epidermal growth factor receptor expressed in baculovirus
- ChEMBL_70623 (CHEMBL678679) In vitro inhibition of Fibroblast growth factor receptor expressed in baculovirus
- ChEMBL_72355 (CHEMBL686442) Binding affinity for Growth factor receptor bound protein 2 SH2 domain
- ChEMBL_72359 (CHEMBL686446) Inhibition of Growth factor receptor bound protein 2 SH2-domain binding
- ChEBML_72490 Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in ELISA
- ChEBML_72495 Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in ELISA
- ChEMBL_158351 (CHEMBL768495) Inhibition of Platelet-derived growth factor receptor (Inactive at 1 mM ATP)
- ChEMBL_213976 (CHEMBL820672) In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2)
- ChEMBL_213978 (CHEMBL817492) In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2
- ChEMBL_305757 (CHEMBL829528) Inhibition of vascular endothelial growth factor receptor 2 in cell-free assay
- ChEMBL_305819 (CHEMBL829472) Inhibition of platelet-derived growth factor receptor alpha in cell-intact assay
- ChEMBL_305820 (CHEMBL829563) Inhibition of vascular endothelial growth factor receptor 2 in cell-intact assay
- ChEMBL_306571 (CHEMBL832088) Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol)
- ChEMBL_306585 (CHEMBL832932) Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol)
- ChEMBL_66717 (CHEMBL674640) Inhibition of the epidermal growth factor receptor expressed in A431 cell line
- ChEMBL_66724 (CHEMBL674647) Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes
- ChEMBL_66895 (CHEMBL675519) Inhibition of epidermal growth factor receptor phosphorylation in BaF3 mouse lymphoid cells.
- ChEMBL_70624 (CHEMBL678680) In vitro inhibition of Fibroblast growth factor receptor 1 expressed in baculovirus
- ChEMBL_72354 (CHEMBL686441) Binding affinity against Growth factor receptor bound protein 2 using ELISA assay
- ChEMBL_72358 (CHEMBL686445) Inhibition against Growth factor receptor bound protein 2 binding using ELISA technique
- ChEMBL_72364 (CHEMBL686601) Inhibitory activity against Growth factor receptor bound protein 2 using ELISA assay
- ChEMBL_72492 (CHEMBL685525) Inhibition of binding to Growth factor receptor bound protein 2 SH2 domain
- ChEMBL_1350287 (CHEMBL3267625) Inhibition of beta-catenin/T cell factor (unknown origin)
- ChEBML_66598 Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells
- ChEBML_66899 In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate)
- ChEBML_70464 Binding affinity for human fibroblast growth factor 1 in surface plasmon resonance (SPR) assay
- ChEBML_72349 Inhibitory concentration against Growth factor receptor bound protein 2 in MDA-MB-453 cells
- ChEBML_72365 Inhibition of Growth factor receptor-bound protein 2 (Grb2) SH2 domain binding by ELISA
- ChEMBL_144432 (CHEMBL753642) Competitive binding against Nerve growth factor to p75-NGF receptor in PC12 cells
- ChEMBL_154586 (CHEMBL761934) Inhibition of platelet-derived growth factor receptor (PDGF-R) from NIH 3T3 cells
- ChEMBL_306384 (CHEMBL828725) Inhibition of mouse Fibroblast growth factor receptor 1 expressed in NIH 3T3 fibroblasts
- ChEMBL_582000 (CHEMBL1055737) Inhibition for IGF1R-induced S6 ribosomal protein phosphorylation in growth factor-stimulated NHDF
- ChEMBL_63767 (CHEMBL677209) In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes
- ChEMBL_66569 (CHEMBL679550) Inhibition of EGF-stimulated autophosphorylation of Epidermal growth factor receptor in A431 cells
- ChEMBL_66570 (CHEMBL679551) Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells
- ChEMBL_67052 (CHEMBL677890) Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined
- ChEMBL_72356 (CHEMBL686443) In vitro Growth factor receptor bound protein 2-binding affinity in ELISA method
- ChEMBL_72360 (CHEMBL686597) Inhibition of Growth factor receptor bound protein 2 binding by ELISA assay method
- ChEMBL_72362 (CHEMBL686599) Inhibition of binding to Growth factor receptor bound protein 2 (Grb2) SH2 domain
- ChEMBL_90284 (CHEMBL697349) In vitro inhibition of Insulin-like growth factor I receptor expressed in baculovirus
- ChEBML_63769 Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts
- ChEBML_72485 Inhibition of Growth factor receptor bound protein 2 SH2 domain binding to p185erbB-2 receptor
- ChEMBL_306228 (CHEMBL831136) In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP
- ChEMBL_313055 (CHEMBL835746) Inhibition of vascular endothelial growth factor (VEGF)-stimulated human umbilical vein endothelial cell proliferation
- ChEMBL_321627 (CHEMBL871636) Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide
- ChEMBL_63600 (CHEMBL675247) Inhibition of human epidermal growth factor 2 (Her-2) degradation in MCF-7 cells
- ChEMBL_63766 (CHEMBL677208) Inhibition of Epidermal growth factor receptor activity against tripeptide RR-Src at 10 uM
- ChEMBL_64442 (CHEMBL674017) Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells
- ChEMBL_66596 (CHEMBL680027) Concentration required to inhibit autophosphorylation of cytoplasmic domain of epidermal growth factor receptor (EGFR)
- ChEMBL_66598 (CHEMBL680029) Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells
- ChEMBL_67043 (CHEMBL677881) In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus
- ChEMBL_67045 (CHEMBL677883) In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus
- ChEMBL_67046 (CHEMBL677884) Inhibition of autophosphorylation of epidermal growth factor receptor (EGF-R) in a cellular assay
- ChEMBL_72363 (CHEMBL686600) Inhibition of Growth factor receptor bound protein 2 SH2 domain in extracellular binding assay
- ChEMBL_72493 (CHEMBL685526) Inhibition of Growth factor receptor bound protein 2 SH2 domain in extracellular binding assay
- ChEBML_70634 Binding affinity for human fibroblast growth factor 2 in surface plasmon resonance (SPR) assay (No binding)
- ChEBML_72488 Inhibition of Growth factor receptor bound protein 2 SH2 domain binding to phospho-EGFR by ELISA
- ChEMBL_154584 (CHEMBL761932) Inhibition of platelet-derived growth factor receptor (PDGF-R) in human aortic smooth muscle cells
- ChEMBL_161599 (CHEMBL769139) Concentration required to inhibit autophosphorylation of cytoplasmic domain of human epidermal growth factor receptor-2
- ChEMBL_213957 (CHEMBL811935) In vitro inhibition of Vascular endothelial growth factor receptor 1 (VEGFR-1) expressed in baculovirus
- ChEMBL_213958 (CHEMBL811936) In vitro inhibition of Vascular endothelial growth factor receptor 1 (VEGFR-1) expressed in baculovirus
- ChEMBL_213975 (CHEMBL812788) In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) expressed in baculovirus
- ChEMBL_66566 (CHEMBL677833) In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).
- ChEMBL_72485 (CHEMBL685518) Inhibition of Growth factor receptor bound protein 2 SH2 domain binding to p185erbB-2 receptor
- ChEMBL_72486 (CHEMBL685519) Dissociation constant for binding to SH2 domain of Growth factor receptor bound protein 2, Grb2
- ChEMBL_72496 (CHEMBL683674) Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in plasmon resonance assay
- ChEMBL_72497 (CHEMBL683931) Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in plasmon resonance assay
- ChEMBL_90401 (CHEMBL698356) The compound was tested for binding affinity against insulin-like growth factor binding protein 1
- ChEMBL_90402 (CHEMBL698357) The compound was tested for binding affinity against insulin-like growth factor binding protein 2
- ChEMBL_90406 (CHEMBL698361) The compound was tested for binding affinity against Insulin-like growth factor binding protein 4
- ChEMBL_90407 (CHEMBL698362) The compound was tested for binding affinity against Insulin-like growth factor binding protein 4
- ChEMBL_90544 (CHEMBL700614) The compound was tested for binding affinity against Insulin-like growth factor binding protein 5
- ChEMBL_90545 (CHEMBL700615) The compound was tested for binding affinity against Insulin-like growth factor binding protein 6
- ChEMBL_1647981 (CHEMBL3997037) Inhibition of recombinant human TrkA expressed in DHFR deficient CHO cells assessed as inhibition of human beta-nerve growth factor-induced calcium influx by Fluo-4 AM dye based assay
- ChEBML_214087 Inhibition of vascular endothelial growth factor receptor 2 activity with 1 mM ATP and biotinylated lck peptide
- ChEBML_214092 Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.
- ChEBML_66902 Inhibition of Grb-SH2 domain binding to phosphorylated carboxy-terminal intracellular domain of epidermal growth factor receptor
- ChEMBL_105475 (CHEMBL708305) In vitro inhibition of Mast/stem cell growth factor receptor (c-Kit kinase) expressed in baculovirus
- ChEMBL_105476 (CHEMBL708306) In vitro inhibition of Mast/stem cell growth factor receptor (c-Kit kinase) expressed in baculovirus
- ChEMBL_63758 (CHEMBL679946) Concentration required to inhibit phosphorylation of isolated human epidermal growth factor tyrosine kinase receptor by 50%
- ChEMBL_64443 (CHEMBL674018) Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR)
- ChEMBL_66575 (CHEMBL679676) Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR)
- ChEMBL_66576 (CHEMBL856168) Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR)
- ChEMBL_67040 (CHEMBL677878) Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity
- ChEMBL_70634 (CHEMBL678690) Binding affinity for human fibroblast growth factor 2 in surface plasmon resonance (SPR) assay (No binding)
- ChEMBL_72351 (CHEMBL686438) Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in plasmon resonance binding assay
- ChEMBL_72368 (CHEMBL680931) Inhibition of Growth factor receptor bound protein 2 SH2 domain binding in plasmon resonance binding assay
- ChEMBL_90408 (CHEMBL698363) Dissociation constant binding to Insulin-like growth factor binding protein 5 at the residue L-81
- ChEMBL_90424 (CHEMBL698181) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L73
- ChEMBL_90425 (CHEMBL698182) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L81
- ChEMBL_90426 (CHEMBL697415) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue R87
- ChEMBL_90427 (CHEMBL697416) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue S85
- ChEMBL_90428 (CHEMBL697417) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y50
- ChEMBL_90429 (CHEMBL697418) Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y86
- Biochemical Binding Assay Biochemical binding assays (DiscoveRx) and in vitro enzyme inhibition assays (LanthaScreen, Life Technologies) were conducted to determine the binding affinity and inhibition activities of CYT-0387 to Type-I BMPR-kinases (ALK2, ALK3, and ALK6) were conducted. Transforming growth factor beta receptor 1 (TGFBR1, ALK5) was used as a control to determine the selectivity to Type-I BMPR-kinases.
- ChEMBL_214249 (CHEMBL820848) In vitro inhibition of Vascular endothelial growth factor receptor 3 [VEGFR-3(Flt-4)] expressed in baculovirus
- ChEMBL_63615 (CHEMBL676159) Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).
- ChEMBL_72357 (CHEMBL686444) In vitro Growth factor receptor bound protein 2-binding affinity in in surface plasmon resonance (SPR) method
- ChEMBL_767244 (CHEMBL1825356) Inhibition of ALK in human KARPAS299 cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_767247 (CHEMBL1825359) Inhibition of RON in mouse 3T3 cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_767249 (CHEMBL1825361) Inhibition of AXL in human HEK293 cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_767252 (CHEMBL1825364) Inhibition of TIE2 in mouse 3T3-E cells assessed growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_767352 (CHEMBL1825464) Inhibition of IR in human HEK293 cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_767355 (CHEMBL1825467) Inhibition of LCK in human Jurkat cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEMBL_90281 (CHEMBL697346) Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Insulin-like growth factor I receptor
- ChEMBL_90409 (CHEMBL698364) Dissociation constant in BS binding to Insulin-like growth factor binding protein 5 at the residue K91
- ChEMBL_90410 (CHEMBL698365) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue K91
- ChEMBL_90411 (CHEMBL698366) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue L73
- ChEMBL_90412 (CHEMBL698367) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue L81
- ChEMBL_90413 (CHEMBL698368) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue R87
- ChEMBL_90414 (CHEMBL698369) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue S85
- ChEMBL_90415 (CHEMBL698218) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue Y50
- ChEMBL_90416 (CHEMBL698219) Dissociation constant in DMSO binding to Insulin-like growth factor binding protein 5 at the residue Y86
- ChEMBL_90417 (CHEMBL698220) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue K91
- ChEMBL_90418 (CHEMBL698221) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue L73
- ChEMBL_90419 (CHEMBL698222) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue L81
- ChEMBL_90420 (CHEMBL698223) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue R87
- ChEMBL_90421 (CHEMBL698838) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue S85
- ChEMBL_90422 (CHEMBL698839) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue Y50
- ChEMBL_90423 (CHEMBL698180) Dissociation constant in PBS binding to Insulin-like growth factor binding protein 5 at the residue Y86
- ChEBML_1565754 Inhibition of human recombinant hepatocyte growth factor activator using H2N(EEdansyl)GKQLRVVNGG (KDabcyl)-NH2 as substrate by fluorometric analysis
- ChEBML_70635 In vitro inhibition against autophosphorylation of Fibroblast growth factor receptor 2 in the human scirrhous gastric carcinoma cell line
- ChEBML_72366 Inhibitory concentration required against Src homology (SH2) domain of Growth factor receptor bound protein 2 by ELISA binding assay
- ChEMBL_213979 (CHEMBL817493) Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells
- ChEMBL_302172 (CHEMBL829239) In vitro binding affinity for growth factor receptor bound protein 2 SH2 domain from human breast cancer cells
- ChEMBL_302173 (CHEMBL830076) In vitro binding affinity for growth factor receptor bound protein 2 SH2 domain from human breast cancer cells
- ChEMBL_72369 (CHEMBL680932) Inhibitory activity against binding of Growth factor receptor bound protein 2 to biotinylated KPFY*VNVEF Peptide by ELISA.
- ChEMBL_767349 (CHEMBL1825461) Inhibition of ABL in mouse BaF3-BCL cells assessed as growth factor-induced autophosphorylation by sandwich ELISA method
- ChEBML_63768 In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay
- ChEBML_72500 Dissociation constant of compound was determined from affinity of compound towards Growth factor receptor bound protein 2 measured by fluorescence
- ChEMBL_1462508 (CHEMBL3398981) Binding affinity to basic fibroblast growth factor (unknown origin) using sugar chip immobilized compound by surface plasmon resonance method
- ChEMBL_1565754 (CHEMBL3782552) Inhibition of human recombinant hepatocyte growth factor activator using H2N(EEdansyl)GKQLRVVNGG (KDabcyl)-NH2 as substrate by fluorometric analysis
- ChEMBL_63765 (CHEMBL677207) In vitro inhibition of intrinsic tyrosine protein kinase activity of the Epidermal growth factor receptor using tripeptide RR-Src
- ChEMBL_1871017 (CHEMBL4372184) Inhibition of human beta-factor 12a using Ac-QRFR-pNA as substrate after 30 mins
- ChEMBL_1515019 (CHEMBL3616083) Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay
- ChEMBL_2296904 Inhibition of human heparanase assessed as reduction in basic fibroblast growth factor binding incubated for 2 hrs by microplate reader assay
- SMAD Transcription Factor Inhibitors Dose Response Confirmation NIH Molecular Libraries Screening Centers Network [MLSCN] Emory Chemical Biology Discovery Center in MLSCN Assay provider: F.M. Hoffmann, University of Wisconsin-Madison MLSCN Grant: 1R21NS057002-01 Assay Overview: Transforming growth factor beta (TGF-Beta) regulates a variety of processes in mammalian cells, including proliferation, apoptosis, cell migration and extracellular matrix production. Aberrant increases in TGF-Beta signaling have been implicated in several pathological conditions including cancer and fibrosis. Inhibition of TGF-Beta signaling is an important tool in elucidating the multiple biological functions of TGF-Beta and is of significant interest as a potential therapeutic strategy in fibrotic diseases and several advanced cancers. Smad proteins mediate cellular responses to TGF-Beta. TGF-Beta alters cellular gene expression and cell behavior by binding and activating the Type II and Type I serine kinase receptors on the cell membrane. Activated Type I recep
- SMAD Transcription Factor Inhibitors Secondary Dose Response Confirmation NIH Molecular Libraries Screening Centers Network [MLSCN] Emory Chemical Biology Discovery Center in MLSCN Assay provider: F.M. Hoffmann, University of Wisconsin-Madison MLSCN Grant: 1R21NS057002-01 Assay Overview: Transforming growth factor beta (TGF-Beta) regulates a variety of processes in mammalian cells, including proliferation, apoptosis, cell migration and extracellular matrix production. Aberrant increases in TGF-Beta signaling have been implicated in several pathological conditions including cancer and fibrosis. Inhibition of TGF-Beta signaling is an important tool in elucidating the multiple biological functions of TGF-Beta and is of significant interest as a potential therapeutic strategy in fibrotic diseases and several advanced cancers. Smad proteins mediate cellular responses to TGF-Beta. TGF-Beta alters cellular gene expression and cell behavior by binding and activating the Type II and Type I serine kinase receptors on the cell membrane. Activated Type I recep
- ChEMBL_651369 (CHEMBL1227189) Inhibition of tissue factor/factor 7a
- ChEMBL_1871019 (CHEMBL4372186) Inhibition of activated beta-factor 11 (unknown origin) using Bz-FVRpNA as substrate after 30 mins
- ChEMBL_1578583 (CHEMBL3811624) Inhibition of human Tissue factor/factor 7a
- ChEMBL_572140 (CHEMBL1024282) Inhibition of human tissue factor/factor 7a
- ChEMBL_655601 (CHEMBL1244645) Binding affinity to tissue factor/factor 7a
- ChEBML_72352 In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined
- ChEMBL_822349 (CHEMBL2038727) Agonist activity at GPR35 in human U20S cells expressing beta-lactamase and Gal4-VP16 transcription factor assessed as beta arrestin translocation after 5 hrs by Tango assay
- ChEMBL_49161 (CHEMBL872476) Inhibitory constant against Coagulation factor Xa (factor Xa)
- ChEMBL_510234 (CHEMBL1005612) Inhibition of human factor 7a-tissue factor complex
- ChEMBL_741022 (CHEMBL1764208) Inhibition of IKK-beta in human PBMC assessed as TNF-alpha-induced Nuclear factor-kappa-B nuclear translocation
- ChEBML_72489 Competitive binding affinity against Growth factor receptor bound protein 2 was assessed using SHC(pTyr-317) phospopeptide in biacore surface plasmon resonance (SPR) method
- ChEMBL_72352 (CHEMBL686439) In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined
- In vitro kinase inhibition assay An in vitro kinase assay was performed to evaluate the kinase suppression activity of the most promising cytotoxic candidates 4b, 4j against four different receptor tyrosine kinases (RTKs) - namely epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER2), vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor (PDGFR). The activities of the examined compounds against EGFR, HER2, PDGFR-β, and VEGFR2 were in vitro tested using Abcam's Human In cell ELISA Kit (ab 126419) for EGFR, ADP-Glo TM Kinase Assay for Her2, PDGFR-β, active, recombinant protein expressed in Sf9 cells for VEGFR2 (KDR) Kinase Assay Kit Catalog No. 40325, respectively.
- ChEMBL_823234 (CHEMBL2040652) Plaque growth inhibition
- ChEMBL_508121 (CHEMBL1004858) Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay
- ChEBML_51277 Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 beta (30% inhibition at 100 uM)
- ChEMBL_533476 (CHEMBL986968) Inhibition of IL-1-beta-induced tissue factor activity in human PBMC preincubated for 4 hrs assessed after 5 hrs of IL1-beta challenge by one stage clotting assay
- ChEMBL_749238 (CHEMBL1781181) Antagonist activity at S1P4 receptor in human U2OS cells expressing EDG6-linked GAL4-VP16 transcription factor via TEV protease site/beta-arrestin/TEV protease fusion protein and beta-lactamase reporter gene assessed as beta-lactamase expression by FRET assay
- ChEMBL_1671573 (CHEMBL4021602) Inhibition of tissue factor/factor 7a activated human coagulation factor-10a using S2765 as substrate pretreated with substrate for 15 mins followed by enzyme and tissue factor/factor 7a addition measured for 60 mins
- ChEMBL_1871029 (CHEMBL4372196) Inhibition of activated beta-factor 11 (unknown origin) using Bz-FVRpNA as substrate after 30 mins relative to untreated control
- ChEMBL_51277 (CHEMBL664979) Antagonistic activity against [125I]-Tyr-ovine CRF binding to Corticotropin releasing factor receptor 2 beta (30% inhibition at 100 uM)
- ChEMBL_550824 (CHEMBL995691) Inhibition of amidolytic activity of human tissue factor/human factor 7a
- ChEMBL_72367 (CHEMBL685573) The compound was evaluated for its potency to inhibit the interaction between Growth factor receptor bound protein 2 and phosphotyrosine-containing peptides derived from Shc Y317
- ChEMBL_1871023 (CHEMBL4372190) Inhibition of activated beta-factor 9 (unknown origin) using Boc-QGR-MCA as substrate after 30 mins relative to untreated control
- ChEMBL_1871025 (CHEMBL4372192) Inhibition of activated beta-factor 12 (unknown origin) using Ac-QRFR-pNA as substrate after 30 mins relative to untreated control